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Abstract (English) 
Background. Perfluoroalkylated substances (PFAS) are persistent organic pollutants that accumulate 
in the fish, wildlife, and humans. In 2013, it has been discovered an area of the Veneto Region in 
which ground water, surface water, and drinking water were contaminated by PFAS. Appropriate 
interventions have been undertaken to contain the water pollution, reducing it effectively. However, 
it has been estimated that the contamination had started about fifty years before its discovery, leading 
to the long-term exposure of the population. The long-term exposure to PFAS is worrying because 
PFAS have been suggested to affect human health. Veneto Region has therefore organized a health 
surveillance programme of the population living in the polluted area. A specific aspect of such 
programme concerns the maternal and newborn health, which represents the focus of my PhD 
research project. The aims of the project were to review animal and human evidence related to this 
topic and to assess the effects of the exposure to PFAS on maternal and newborn health in the 
population living in the polluted area of Veneto Region. 
Methods. The systematic review included relevant studies in the English language identified through 
the online database PubMed. Studies were eligible to the review if they assess the effect of PFAS 
exposure during the reproductive period on the health of the pregnant women and of the infant. 
The identification of the outcomes of interest assessed in the study about maternal and newborn health 
in Veneto Region was based on the systematic review. The outcomes investigated were preeclampsia 
and gestational diabetes mellitus (GDM) (pregnancy complications), and intrauterine growth 
restriction, evaluated using a proxy of fetal growth, the Small for Gestational Age (SGA) (birth 
outcomes). The study was performed using an indirect measure of exposure to PFAS, defined as 
woman’s residence in the contaminated area (including 21 municipalities identified according to a 
Veneto Region Official Resolution). A control area that included 48 municipalities not exposed to 
PFAS contamination according to the performance limits of the National Institue of Health was 
chosen for comparision. The information sources included two administrative datasets, the Veneto 
Region Birth Registry and the Veneto Region hospital discharge records. For the pregnancy 
complications (preeclampsia and GDM), a medical chart review of pregnant women hospitalized is 
ongoing to validate the cases identified from the hospital discharge records.  
Results. The systematic review led to the retrieval of 1096 records from PubMed. One hundred and 
thirty-nine records were judged to be eligible to the study. Overall, evidence retrieved suggests that 
PFAS exposure might affect the health of the pregnant woman and the development of the fetus. 
The epidemiological study showed that newborns of mothers living in the contaminated area were 
significantly more likely to be SGA compared to newborns of mothers living in the control area 
(adjusted Odds Ratio 1.26, 95% C.I. 1.14-1.38). Looking at pregnancy complications (preeclampsia 
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and GDM), preliminary results were available because the review of the medical chart is ongoing. 
Such preliminary results seem to suggest that the frequency of these pathological conditions is slightly 
higher in women living in the contaminated area compared to those living in the control ones. 
However, they must be taken with caution because the validation of preeclampsia and GDM cases is 
ongoing. 
Conclusions. The results of the present research project suggest that PFAS exposure might affect 
maternal and newborn health. The present topic deserves further research, not only from the 
epidemiological point of view, but also for what concerns the pathophysiological mechanisms 
potentially involved in the association between PFAS exposure and adverse health outcomes in 
pregnant women and newborns.  
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Abstract (Italiano) 
Razionale. Le sostanze perfluoroalchiliche (PFAS) sono inquinanti organici persistenti. Nel 2013, la 
scoperta di un’area inquinata da PFAS nella Regione Veneto ha portato all’immediata adozione di 
interventi atti al contenimento della contaminazione. Tuttavia, si stima che la contaminazione sia 
iniziata circa cinquant’anni prima della sua scoperta, determinando un’esposizione di lungo corso 
della popolazione. Questa scoperta ha destato grande preoccupazione poichè è stato suggerito che gli 
PFAS abbiano effetti avversi sulla salute umana. La Regione Veneto ha quindi attivato un piano di 
sorveglianza sanitaria della popolazione esposta. Un aspetto specifico di questo programma riguarda 
la salute materno-infantile che ha costituito il focus del mio progetto di Dottorato. Il progetto aveva 
come obiettivi quello di effettuare una revisione delle evidenze sull’animale e l’uomo riguardo questo 
tema e di condurre uno studio epidemiologico sulla salute materno-infantile della popolazione esposta 
nella Regione Veneto. 
Metodi. Nella revisione sistematica sono stati inclusi tutti gli studi pertinenti, in lingua inglese, 
identificati dal motore di ricerca PubMed. Gli studi venivano considerati pertinenti se valutavano 
l’effetto dell’esposizione a PFAS, durante il periodo riproduttivo, sulla crescita intrauterina e le 
anomalie congenite strutturali e funzionali (esiti sul nato) e sul rischio di sviluppare preeclampsia, 
diabete gestazionale e disturbi della tiroide (esiti sulla donna in gravidanza).  
Sulla base della revisione, sono stati identificati gli esiti di salute materno-infantile analizzati nello 
studio epidemiologico. Nello specifico, sono stati valutati il rischio di preeclampsia e diabete 
gestazionale (esiti sulla donna in gravidanza) e quello di nascere piccolo per l’età gestazionale (SGA: 
Small for Gestational Age) come proxy di crescita intrauterina. Lo studio ha utilizzato una misura 
indiretta di esposizione a PFAS rappresentata dalla residenza della donna nell’area contaminata (che 
include 21 Comuni identificati da una Deliberazione della Giunta Regionale della Regione Veneto). 
È stata inoltre identificata un’area di controllo impiegata come termine di confronto. Le fonti 
informative utilizzate sono state il Registro Nascita e le Schede di Dimissione Ospedaliere (SDO) 
della Regione del Veneto. Per quanto riguarda gli esiti sulla donna in gravidanza (preeclampsia e 
diabete gestazionale), è in corso un processo di validazione dei casi identificati dalle SDO, mediante 
la revisione delle cartelle delle donne ricoverate. 
Risultati. La revisione sistematica ha identificato 1096 risultati, lo screening dei quali ha portato 
all’inclusione di 139 risultati. Gli studi inclusi sembrano suggerire che l’esposizione a PFAS possa 
influenzare negativamente la salute della donna in gravidanza e lo sviluppo del nato, sia nel breve 
che nel lungo termine. 
Lo studio epidemiologico mostra che i nati da madri residenti nell’area contaminata hanno una 
probabilità significativamente maggiore di nascere SGA rispetto ai nati da madri residenti nell’area 
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di controllo (Odds Ratio aggiustato 1.26, 95% I.C. 1.14-1.38). Per quanto riguarda gli esiti sulla donna 
in gravidanza, vengono presentati i risultati preliminari in quanto la revisione delle cartelle è in corso. 
Questi risultati sembrano suggerire che la frequenza degli esiti di interesse (preeclampsia e diabete 
gestazionale) sia maggiore nelle donne nell’area contaminata rispetto a quella nelle donne nell’area 
di controllo.  
Conclusioni. I risultati del presente progetto di ricerca sembrano suggerire che l'esposizione a PFAS 
possa influire sulla salute della madre e del neonato. Questo argomento merita ulteriori ricerche, non 
solo dal punto di vista epidemiologico, ma anche riguardo i meccanismi patofisiologici 
potenzialmente coinvolti nell'associazione tra esposizione a PFAS ed esiti di salute avversi sulla 
donna in gravidanza e sul nato.  
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Preface 
This thesis is the result of the research project that I have developed during my PhD Programme in 
Developmental Medicine and Health Planning Sciences (curriculum: Health Planning Sciences), and 
it concerns the relation between exposure to Perfluoroalkylated substances (PFAS) and mother-child 
health outcomes.   
This research project derives from a public health issue in the Veneto Region. In 2013, after some 
experimental studies requested by the Ministry of Environment over potentially pollutant substances, 
the presence of PFAS was discovered in the ground water, surface water, and drinking water in an 
area of the Veneto Region. This pollution is considered to be due to the release of these substances 
from a chemical plant located in the polluted area.   
The discovery of the contamination triggered the immediate activation of a series of measures aimed 
to contain the pollution of drinking water, reducing it effectively. However, the water pollution has 
first occurred some fifty years before its discovery, thus involving a long-term exposure of the 
population living in the contaminated area. The fact that the population has been exposed for many 
years, through consumption of contaminated tap water, is a cause of concern. PFAS are persistent 
environment pollutants, known for their adverse effects on human health, some suspected and some 
proved by a wide range of studies. Veneto Region has therefore organized a programme aimed at the 
surveillance of population living in the polluted areas. A specific aspect of this activity concerns 
mother-child health, the aspect on which my PhD research was focused.  
The choice of focusing on the effects of PFAS exposure over mother-child health is due to the fact 
that studies over this topic have shown that, not only PFAS accumulate in the body through the 
ingestion of polluted water but also fetus and breastfed newborn are exposed to PFAS through 
placental and lactational transfer, respectively.   
My activities within this research project included the systematic revision of scientific evidence on 
exposure to PFAS and mother-child health and contributing to the development of a study of the 
effects of the exposure to PFAS on maternal and newborn health in the population living in the 
polluted area of the Veneto Region. Furthermore, I had the chance to deepen my knowledge of 
environmental epidemiology applied to PFAS research during an internship that took place at the 
WHO European Centre for Environment and Health (ECEH), which is part of the WHO Regional 
Office for Europe, located in Bonn, Germany. 
These activities have resulted in the preparation of three papers, thought as standalone manuscripts, 
that constitute this thesis, which represents the result of the research project followed during my PhD 
Programme. The first paper introduces the theme of the relation between PFAS and mother-child’s 
health outcomes through a systematic revision of bibliography related to this topic. The other two 
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papers report the results of the epidemiological study. Specifically, the second paper presents the 
preliminary results of the analysis of the epidemiology of pregnancy complications (gestational 
diabetes and preeclampsia) in pregnant women living in the contaminated area of the Veneto Region. 
The last paper describes the results of the study of intrauterine growth restrictions (birth outcome) in 
the newborns of mothers living in the contaminated area of the Veneto Region.   
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Systematic review of human and animal evidence on the effect of PFAS exposure on maternal 
and newborn health 
 
1. Introduction 
Perfluoroalkylated substances (PFAS) are chemical substances industrially produced. They present 
characteristics of repulsion to both fats and water, chemical stability, and all-round persistence. 
Because of these characteristics, they have been widely used both in domestic and industrial use. 
They can be found in a wide range of widely distributed products, for example, food containers 
(because of their non-stick characteristics) and fabrics (to make them water or fat repellent). These 
are just a few examples of a large range of applications.   
At the beginning of the 2000s some instances have been reported where water was polluted by these 
substances. This discovery raised doubts over the safety of these substances, and various studies have 
been elaborated to assess their real effect over the environment, the animal kingdom, and of course 
for humans. These studies uncovered that these substances are persistent in the environment, toxic to 
animals, and they can produce adverse effects on humans (U.S. Environmental Protection Agency 
2016b, 2016a). The PFAS most wideley produced and studied are the Perfluorooctanoic acid (PFOA) 
and the perfluorooctane sulfonate (PFOS), which are long-chain PFAS characterized by eight-carbon 
backbone (the distinction between short- and long-chain PFAS depends on the number of carbon 
atoms, with usually 6 carbon atoms used as a cut-off). As a result of such studies, the production and 
use of PFOA and PFOS have been restricted in recent years (PFOS, in particular, is listed in 
Stockholm Convention’s criteria of persistent organic pollutant (Secretariat 2009)). 
Several health effects have been hypothesized to be related to PFAS exposure (U.S. Environmental 
Protection Agency 2016a, 2016b), including some types of cancer (Benbrahim-Tallaa et al. 2014). 
An area over which PFAS research concentrated is the one concerning mother-newborn health. This 
area of research is motivated by the fact that pharmacokinetic studies over animals have demonstrated 
that PFAS are transferred from mother’s blood to placenta during gestation and to mother’s milk after 
birth, thus exposing fetus and newborn (Loccisano et al. 2012). These observations have been 
confirmed by successive studies regarding body burden of PFAS on humans and, in particular, on the 
pregnant woman. It has been in fact demonstrated a strong correlation between PFAS concentration 
in mother’s blood, umbilical cord, and placenta (with decreasing concentration) (Glynn et al. 2012; 
Manzano-Salgado et al. 2015). Recent studies have shown that the strongest predictors of PFAS 
concentration in a pregnant woman are precedent pregnancy, having breast-fed, and length of the 
breast-feeding (Berg et al. 2014; Brantsæter et al. 2013; Sagiv et al. 2015). Women that have given 
birth and breast-fed have a lower concentration of PFAS in their blood compared to women that have 
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not had children yet (Berg et al. 2014; Brantsæter et al. 2013; Sagiv et al. 2015). A recent study has 
shown that, because of the exposure in the uterus, and because of breast-feeding, the body burden of 
PFAS in 6 months old subjects is comparable, if not higher, of the body burden in an adult (Fromme 
et al. 2010).   
It is also interesting to observe how the efficiency of PFAS transfer from mother’s blood to the 
placenta and breast milk can vary according to the characteristics of this substance. In particular, even 
though PFOA and PFOS are PFAS that contribute the most to the body burden of these substances, 
partitional analysis of these substances in mother’s blood samples and umbilical cord samples 
suggests that short chain PFAS have a higher transfer rate (Gützkow et al. 2012; S.-K. Kim et al. 
2011). These observations testify that not only PFOA and PFOS are a risk for human health, but also 
other kinds of PFAS that have been taken less into consideration so far, require a careful analysis of 
their potential effects on health.   
Regarding pharmacokinetic of PFAS in the fetus and the newborn, studies are available in limited 
quantity, nonetheless available data are worrying. Studies over the distribution of PFAS in fetus and 
animal offspring showed that just like in adults, fetuses and offspring accumulate PFAS mostly in the 
liver, lungs, and kidneys. In fetuses and offspring, however, we can also observe high concentration 
of PFAS even in the brain (Borg et al. 2010; Onishchenko et al. 2011), therefore opening the 
discussion of possible neurodevelopmental effects of this exposure in the brain of the newborn.   
Taking into consideration that the exposure to chemical substances in a crucial time, as the one spent 
in uterus or during the first months of life, can be detrimental because it can affect structural and 
functional development resulting in adverse health outcomes, the number of studies published over 
this subject has exponentially increased in less than twenty years.  
Some specific aspects (such as the effect of exposure to PFAS over the intrauterine growth) have 
been deeply studied more than other ones and have been subject to systematic reviews and 
metanalysis. However, a systematic approach to the evidence published so far over the exposure to 
PFAS for maternal and newborn health is still missing. For this reason, we have proceeded into a 
systematic review over this topic.  
 
2. Materials and Methods 
2.1 Search strategy 
Relevant studies in the English language published before the 5th of July 2018 were identified through 
the online database PubMed. The search string was made of two parts, the first one referred to the 
substances of interest (adapted from the search strategy employed in the US Enviromental Protection 
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Agency (EPA) report (U.S. Environmental Protection Agency 2016b, 2016a)) and the second one 
referred to the outcomes of interest (Table 1). No limits were applied to publication date. 
2.2 Study selection and data extraction 
The study aimed to review animal and human evidence of an association between PFAS exposure 
and maternal/newborn health. The study selection criteria were identified using two PICO 
(Participants, Intervention/Exposure, Comparator, and Outcomes) approaches (Higgins 2015) (one 
for animal and the other one for human evidence) (Table 2).  
If a study was judged eligible to the review, then the information of interest was extracted. The 
information extracted for animal studies included the specie, the exposure, the route of exposure, the 
dose (range), the period of exposure, the outcome/s investigated. The information reported for human 
studies were the study design, the location in which the study took place, the population of interest, 
the exposure, the biological matrix (if any) on which the exposure was measured, and the outcome/s 
investigated. Studies’ findings were summarized by reporting only the statistically significant results 
for the outcomes of interest adjusted for potential confounders (unless otherwise specified) if 
regression approaches were employed. 
3. Results 
The study selection procedure is reported in Figure 1 (PRISMA flow-chart). Briefly, 1096 records 
were retrieved from PubMed. The title/abstract screening led to the exclusion of 791 records. As a 
result, the full-text of 305 articles underwent the assessment for eligibility. One hundred and thirty-
nine studies were judged to be eligible. Eighty-one out of 139 records reported evidence from human 
studies. The types of chemical substances investigated are reported in Table 3. Studies characteristics 
and results are summarized in Table 4 and 5 (animal and human evidence, respectively). 
3.1 Animal studies 
Fifty-eight records reported evidence from animal studies starting from 1984 (Table 4). Animals most 
frequently involved were the rat and the mouse (32 records). Among the non-mammalians, the 
zebrafish was the animal most frequently involved (14 records). Three records reported studies 
involving two species of animal (rat/mouse, rat/rabbit) (Case, York, and Christian 2001; Lau et al. 
2003; Thibodeaux et al. 2003). All the studies included a control group not receiving PFAS. The 
exposure to PFOA and PFOS (either alone or in combination) was the most frequently investigated. 
The exposure to other types of PFAS has been investigated less frequently and only since the end of 
2010, including both short-chain PFAS and long-chain PFAS. 
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3.2 Human studies 
Eighty-one studies were included, corresponding to 38 datasets, published since 2007 (Table 5). In 
most cases they were birth cohort studies. PFAS exposure was most often directly measured in 
maternal blood during pregnancy, followed by cord blood. Only in four studies an indirect measure 
of in-utero exposure was estimated (Nolan et al. 2009, 2010; Savitz, Stein, Elston, et al. 2012; Savitz, 
Stein, Bartell, et al. 2012). In most cases, the exposure to several PFAS (both long- and short-chain) 
besides PFOA and PFOS was measured. The outcome most frequently investigated was the 
intrauterine growth restriction.  
3.3 Relationship between PFAS exposure and the outcomes of interest 
Animal and human evidence of association for the outcomes of interest is reported in following 
sections. 
 
3.3.1 Pregnancy complications (Preeclampsia and Gestational Diabetes Mellitus) 
Epidemiological studies that have investigated the relationship between PFAS exposure and the risk 
of developing preeclampsia and gestational diabetes mellitus during pregnancy are scant, if compared 
to those about intrauterine growth restrictions. It is noteworthy that the exposure to PFOA and PFOS 
has been suggested to be related to significantly higher gestational weight gain (Ashley-Martin et al. 
2016; Jaacks et al. 2016). In addition to that, looking at the lipid panel, blood cholesterol was found 
to have a significant positive association in pregnant women with PFOA and PFOS (Skuladottir et al. 
2015), while triglycerides were found to be inversely associated with PFOA, PFOS, and PFNA (Kishi 
et al. 2015; Matilla-Santander et al. 2017). Looking specifically at the risk of gestational diabetes 
mellitus, Zhang et al. have shown that it was significantly positively associated with PFOA in 
pregnant women (C. Zhang et al. 2015). A recent study based on a Spanish birth cohort, besides 
confirming such finding, has further shown that impaired glucose tolerance in pregnant women had 
a positive relationship with PFOA, PFOS, and PFHxS in the blood (Matilla-Santander et al. 2017). 
As for gestational diabetes mellitus, evidence about the relationship of PFAS with pregnancy-induced 
hypertension (PIH) and preeclampsia is inconsistent. Savitz et al. published a study showing no 
significant association between PFAS and PIH (Savitz, Stein, Elston, et al. 2012). The year after, 
Darrow et al. showed that PIH was significantly positively associated with PFOA and PFOS (Darrow, 
Stein, and Steenland 2013). Only weak or no association was found out with preeclampsia (Savitz, 
Stein, Bartell, et al. 2012; Starling et al. 2014; Stein, Savitz, and Dougan 2009). 
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3.3.2 Intrauterine growth restrictions 
Two reviews, conducted using the Navigation Guide methodology, specifically developed for 
environmental health evidence revision (Woodruff and Sutton 2014), over the effect of PFOA on fetal 
growth have concluded that there is sufficient evidence of an association between prenatal exposure 
to PFOA and intrauterine growth restrictions both in animals and humans (Koustas et al. 2014; 
Johnson et al. 2014). Conversely, a further review published one year later by Bach and colleagues 
about the epidemiological evidence on the effect of PFOA and PFOS exposure on in-utero human 
growth concluded that evidence is still inconclusive, even if it seems that growth is affected by high 
concentrations of PFOA and PFOS (Bach et al. 2015). Not least, a very recent meta-analysis on 24 
human studies concluded that there is only modest evidence of an inverse association between PFOA 
and birthweight (Steenland, Barry, and Savitz 2018). 
Undoubtedly, fetal growth is the birth outcome most widely studied in the field of PFAS research. 
From the public health perspective, it is of great relevance since fetal growth restrictions are a strong 
predictor of morbidity and mortality. 
Non-mammalian studies showed that body length is significantly lower in zebrafish exposed to PFOA 
and PFOS (Dang, Wang, and Liu 2018; Hagenaars et al. 2011; Jantzen et al. 2016; Shi et al. 2008). 
In addition to that, it has been shown that larvae volume and pupa weight is significantly lower in 
fruit fly exposed to PFOA (J. Wang et al. 2010). In rats and mice, it has been shown that both fetal 
and pups weights are significantly affected mainly by PFOA and PFOS exposure (Case, York, and 
Christian 2001; Lau et al. 2003; Thibodeaux et al. 2003; Butenhoff et al. 2004; Grasty et al. 2003; 
Iwai and Hoberman 2014; Lau et al. 2006; C. K. Lee et al. 2015; X. Li et al. 2016; Rogers et al. 2014; 
Staples, Burgess, and Kerns 1984; Suh et al. 2011; White et al. 2007, 2011; Wolf et al. 2007; Yahia 
et al. 2010) and, when placental weight was assessed (as a proxy of nutrient transport efficiency), an 
inverse association with PFAS exposure was found (C. K. Lee et al. 2015; X. Li et al. 2016; Suh et 
al. 2011). 
Epidemiological studies considered a wide variety of proxies of intrauterine growth restriction, 
including birth weight (continuous or z-score), low birth weight (LBW) (birth weight <2500g), birth 
length, abdominal circumference, chest circumference, ponderal index (PI), being small for 
gestational age (SGA) (weight below the 10th percentile for the gestational age), and body mass index 
(BMI). Such a variety of endpoints makes it difficult to compare the results from different studies. 
The growth endpoint most widely studied was the birth weight (treated as a continuous variable). 
Most of the studies that evaluated the birth weight found out a significant inverse association with 
some PFAS, in particular with PFOA (Andersen et al. 2010; Fei et al. 2007; Lenters et al. 2016; 
Minatoya et al. 2017; Starling et al. 2017; Wu et al. 2012), PFOS (Bach et al. 2016; M.-H. Chen et 
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al. 2012, 2017; Darrow, Stein, and Steenland 2013; Lauritzen et al. 2017; Washino et al. 2009), or 
both (Apelberg et al. 2007; Kwon et al. 2016; M. Li et al. 2017; Maisonet et al. 2012). Only a small 
number of studies found out a significant inverse association of birth weight with other PFAS, in 
particular with PFHxS and PFNA (Bach et al. 2016; Kwon et al. 2016; Maekawa et al. 2017; Maisonet 
et al. 2012; Y. Wang et al. 2016). Four studies found out higher risk of SGA for newborns exposed 
in-utero to PFOA and PFOS (M.-H. Chen et al. 2012; Govarts et al. 2018; Lauritzen et al. 2017; Y. 
Wang et al. 2016), even if an earlier study showed an inverse association of SGA with PFOS (Hamm 
et al. 2010). Only two out of ten studies that have evaluated the effect of PFAS on LBW found out a 
significant association (Arbuckle et al. 2013; Stein, Savitz, and Dougan 2009). Four studies found 
out a significant association between PI and PFOS/PFOA (Alkhalawi et al. 2016; Apelberg et al. 
2007; Y. J. Lee et al. 2013; Minatoya et al. 2017).  
3.3.3 Structural and functional (nervous system and brain problems) birth defects 
Non-mammalian studies showed that PFOA and PFOS exposure resulted in higher malformation rate 
in a dose- and time-dependent manner in zebrafish (J. Chen et al. 2013, 2014; Dang, Wang, and Liu 
2018; Du et al. 2009; Hagenaars et al. 2011; Huang et al. 2010; Jantzen et al. 2016; Shi et al. 2008; 
M. Wang et al. 2011; L. Zhang et al. 2011; Zheng et al. 2011) and Xenopus (M. Kim et al. 2013). In 
the zebrafish, the malformations involved most often the swim bladder and spine development. PFOA 
in ovo exposure seemed to result in structural and functional heart defects in chicken (Jiang et al. 
2012; Zhao et al. 2017). The impairment of heart function has also been highlighted in the zebrafish 
(Hagenaars et al. 2011; Huang et al. 2010). Mammalian studies have shown that mouse exposed to 
9-30 mg/kg of PFOS between 1-17 gestational days (GDs) presented higher rates of cleft palate (Era 
et al. 2009). Not least, exposure to PFOA has been suggested to result in impaired ossification in rats 
(Lau et al. 2006; Staples, Burgess, and Kerns 1984). Epidemiological evidence (in humans) in the 
field is inconsistent. Three studies did not find significant associations between PFAS exposure and 
birth defects (Nolan et al. 2010; Savitz, Stein, Bartell, et al. 2012; Stein, Savitz, and Dougan 2009), 
while Liew at al found out a significantly higher risk of congenital cerebral plasy in boys exposed in-
utero to PFOA and PFOS (Liew et al. 2014). 
The number of studies specifically about the impact of PFAS exposure on neurodevelopment has 
grown exponentially in the last ten years since animal studies have shown that PFAS could act as 
neurotoxicants. PFAS exposure in zebrafish has shown to result in impaired swim rates (Spulber et 
al. 2014; Ulhaq et al. 2013). Behavioral problems resulting from PFAS exposure have also been 
highlighted in the chicken; it has been shown that in ovo PFAS exposure might result in impaired 
imprinting performance (Pinkas et al. 2010). Mammalian studies have suggested that exposure to 
15 
 
PFOA, PFOS, and PFBA could result in pups’ delayed eye opening (Das et al. 2008; Lau et al. 2003; 
Wolf et al. 2007). In addition to that, PFOA and PFOS exposure seemed to affect motor activity and 
spatial learning in the mouse and the rat (Fuentes et al. 2007; Goulding et al. 2017; Onishchenko et 
al. 2011). Looking at the epidemiological evidence in this field, two reviews have been published in 
the last five years (Berghuis et al. 2015; Roth and Wilks 2014). The last update of that of Roth et al. 
was at the beginning of 2006 and of that of Berghuis et al. was the second semester of 2014. Such 
reviews claimed that evidence in the field is inconsistent mainly due to a great methodological 
heterogeneity in studies conduction, making it difficult to compare study results. Head circumference, 
which could be considered a proxy of brain development, has been found to be in a significant inverse 
association with PFAS exposure only in a small number of studies (Apelberg et al. 2007; M.-H. Chen 
et al. 2012; Y. Wang et al. 2016). Only weak and inconsistent associations have been found out with 
cognitive development in early- and mid-childhood (Stein, Savitz, and Bellinger 2013; Jeddy et al. 
2017; Harris et al. 2018; Goudarzi et al. 2016; Forns et al. 2015; Fei and Olsen 2011; Fei et al. 2008). 
Also, neurobehavioral consequences of PFAS exposure have been studied; however, studies’ findings 
are inconsistent. PFAS exposure seemed to result in a higher risk of hyperactivity and inattention 
(Høyer et al. 2015; Lien et al. 2016), but no consistent associations have been found out with the risk 
of suffering of Attention Deficit Hyperactivity Disorder (ADHD) (Liew et al. 2015; Ode et al. 2014). 
3.3.4 Thyroid function 
A recent review of the relationship between PFAS and thyroid function has suggested that the 
exposure to such chemicals could result in thyroid disorders (Coperchini et al. 2017). Looking at the 
effects of PFAS exposure on thyroid function in pregnant women and newborns is even more relevant 
since thyroid hormones play a key role in the development of the fetus and the child. Animal studies 
suggest that PFAS act as endocrine disruptors resulting in the impairment of thyroid function (in both 
mammalian (Lau et al. 2003; Thibodeaux et al. 2003; Yu et al. 2009) and non-mammalian studies 
(Cassone et al. 2012), PFAS exposure has been put in an inverse relationship with triiodothyronine 
(T3) and thyroxin (T4) levels). 
A review, updated at the end of 2015, about the epidemiological evidence on the effects of PFAS on 
thyroid function during the prenatal period and childhood showed some kind of association between 
PFHxS/PFOS and TSH in maternal blood (Ballesteros et al. 2017). After 2015, new studies have been 
published about such topic. Overall, such studies seemed to confirm the positive association of PFOS, 
PFHxS, PFHpS and TSH in maternal blood (Berg et al. 2017). However, TSH in maternal and cord 
blood seemed to be in an inverse relationship with PFNA. Looking at T3 and T4 levels, T3 in maternal 
and cord blood seemed to be in an inverse relationship with a wide spectrum of PFAS (PFNA, 
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PFUnDA, PFDA, PFOS, PFTrDA) (Berg et al. 2017, 2015; S. Kim et al. 2011; Yang et al. 2016). 
The relationship of T4 levels with PFAS exposure has been studied less frequently; even if scant, 
evidence in the field seemed to suggest that T4 is in an inverse relationship with some PFAS (Y. 
Wang et al. 2014; Preston et al. 2018; S. Kim et al. 2011; Kato et al. 2016). Despite the fact that most 
evidence in the field seemed to suggest that PFAS exposure is in a positive relationship with TSH 
and in an inverse ones with T3 and T4, there are still some exceptions (e.g., it has been shown a direct 
relationship of T3 and T4 with PFPeA and PFHxS in baby girls (Shah-Kulkarni et al. 2016)). Such 
inconsistencies in the evidence about PFAS and thyroid hormones do not allow for drawing 
conclusions about the effect of PFAS on thyroid function during the prenatal period and childhood.  
 
4. Discussion 
The present study aimed at reviewing the evidence about the relationship of PFAS exposure with 
maternal and newborn health. Overall, evidence retrieved suggests that in-utero PFAS exposure might 
affect the development of the fetus and the newborn. However, despite the efforts in improving the 
knowledge and the understanding of PFAS effect on maternal and newborn health, especially in the 
field of fetal growth (testified by the high number of studies in the field identified in this work), the 
evidence is still inconclusive for most of the outcomes considered in the present review. Even if the 
overall studies’ quality was good (all animal studies included a control group and almost all human 
studies presented data from large prospective birth cohorts), studies’ findings are difficult to be 
compared and pooled together due to methodological reasons. Such reasons include the heterogeneity 
in the type of outcomes considered (e.g., eight different proxies of fetal growth were employed in 
epidemiological studies analyzing the effect of PFAS on intrauterine growth restriction), and the way 
in which they were analyzed. Another critical aspect that contributes to the methodological 
heterogeneity is the analysis of the exposure. In human studies, the exposure was measured at 
different time points (e.g., in different time point of pregnancy) on several biological matrixes 
(maternal blood, cord blood, breast milk) making it difficult to compare exposure levels and the 
magnitude of their effect on the endpoints of interest. Although difficult to compare, it is noteworthy 
that, in recent years, the analysis of the exposure has included different types of PFAS other than 
PFOA and PFOS (which are still the PFAS most widely studied) (Ulhaq et al. 2013; Chang et al. 
2018; Das et al. 2015; Iwai and Hoberman 2014; Jantzen et al. 2016; M. Kim et al. 2013; Rogers et 
al. 2014). This is relevant in the field of maternal and newborn health research since it has been shown 
a selective transfer of some PFAS from maternal to cord blood (Gützkow et al. 2012) that should be 
taken into account when the expsoure of the fetus is studied.  
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5. Conclusions 
According to the present findings, it seems that further efforts should be made to harmonize the new 
evidence in the field with the existing ones and to strengthen the knowledge about specific endpoints 
for which evidence are lacking (e.g., birth defects). Such further efforts are essential to developing 
evidence-based public health programs for the monitoring and the care of pregnant women and their 
children exposed to PFAS in highly contaminated areas since the PFAS contamination and the 
subsequent exposure to PFAS of people working or living in contaminated areas represent a severe 
public health burden. This is even more relevant for pregnant women because their exposure to PFAS 
implies the exposure of the developing fetus, which is extremely sensitive to any kind of external 
insult.  
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Table 1. PubMed search string (last update made on the 5th of July 2018) 
N Search string Records 
1 (perfluorooctanoate OR “perfluorooctanoic acid” OR “perfluoroctanoic acid” OR 
pfoa OR “perfluorinated chemicals” OR “perfluorinated compounds” OR 
“perfluorinated contaminants” OR “perfluorinated surfactants” OR perfluoroalkyl 
acids OR “perfluorinated alkylated substances” OR “perfluoroalkylated 
substances” OR pfba OR “perfluorobutanoic acid” OR perfluorochemicals OR 
“telomer alcohol” OR “telomer alcohols” OR “fluorotelomer alcohols” OR 
“polyfluoroalkyl compounds” OR “perfluorooctane sulfonate” OR pfos OR 
“perfluorooctanesulfonic acid” OR “perfluorooctane sulfonic acid” OR 
“perfluorooctane sulphonate” OR “perfluorooctane sulfonate” OR 
“perfluorooctanyl sulfonate” OR perfluorononanoate OR pfhxa OR 
“perfluorohexanoic acid” OR “fluorinated surfactants”)  
4837 
2 (Reproduction[Mesh] OR Reproduction[Title/Abstract] OR "Growth and 
Development"[Mesh] OR "Development and Growth"[Title/Abstract] OR 
Development[Title/Abstract] OR Developmental[Title/Abstract] OR Growth 
[Title/Abstract] OR  “Pregnancy Complications”[Mesh] OR “Pregnancy 
Complication”[Title/Abstract] OR “Pregnancy Complications”[Title/Abstract] OR 
"Developmental Biology"[Mesh] OR "Developmental Biology"[Title/Abstract]) 
4665226 
3 1 AND 2 1096 
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Table 2. PICO (Participants, Intervention/Exposure, Comparator, and Outcomes) approach for animal 
and human evidence 
 
Animals   
Participants Animals (both mammalian and non-mammalian) exposed 
to PFAS during the reproductive phase 
Exposure Any type of PFAS at any dosage by any route of 
administration 
Comparator Animals not exposed to PFAS and/or exposed to different 
doses of PFAS 
Outcomes Intrauterine growth restrictions, structural and functional 
(nervous system and brain problems) birth defects, 
preeclampsia, gestational diabetes, thyroid disorders  
Humans   
Participants Pregnant women and children 
Exposure Direct measure of exposure in maternal blood, cord 
blood, breast milk or estimated (indirect) measure of 
exposure in maternal blood, cord blood, breast milk 
Comparator Continuous or categorized levels of PFAS 
Outcomes Intrauterine growth restrictions, structural and functional 
(nervous system and brain problems) birth defects, 
preeclampsia, gestational diabetes, thyroid disorders 
Study design Retrospective study, prospective study, cross-sectional 
study, case-control study 
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Table 3. Chemical substances investigated in the studies included in the review 
Acronym Full meaning 
PFBA Perfluorobutyric acid 
PFBS Perfluorobutane sulfonate 
PFPeA Perfluoropentanoic acid 
PFHxA Perfluorohexanoic acid 
PFHxS Perfluorohexane sulfonate 
PFOA Perfluorooctanoic acid 
PFOS Perfluorooctane sulfonate 
PFDeA (or PFDA) Perfluorodecanoic acid 
PFDoA (or PFDoDA) Perfluorododecanoic acid 
PFHpA Perfluoroheptanoic acid 
PFHpS Perfluoroheptane sulfonate 
PFHxDA Perfluorohexadecanoic acid 
PFNA Perfluorononanoic acid 
PFOSA Perfluorooctane sulfonamide 
PFTeDA Perfluorotetradecanoic acid 
PFUnA (or PFUnDA) Perfluoroundecanoic acid 
PFTrDA Perfluorotridecanoic acid 
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Table 4. Animal evidence included in the review. Significant adverse effects are in bold 
Author, Year Species Outcome/s Exposure Route Dose (range) Period of exposure Results 
(Abbott et al. 
2007) 
Mouse PW, Eye opening PFOA Gavage 0.1-20 mg/kg 1-17 GDs Eye opening: significantly delayed 
(dose-dependent trend) 
(Boberg et al. 
2008) 
Rat FW PFOA  Gavage 20 mg/kg 7-21 GDs No significant association 
(Butenhoff et al. 
2009) 
Rat GL, MW, Thyroid function 
(pups), Learning/Memory, 
Behavior 
PFOS Gavage 0.1-1 mg/kg 0 GD-20 PND No significant association 
(Butenhoff et al. 
2004) 
Rat PW, Malformations PFOA Gavage 1-30 mg/kg 6 weeks of age-at 
least 70d before 
cohabitation 
PW: significantly lower at 30 mg/kg  
(Case, York, and 
Christian 2001) 
Rat 
Rabbit 
MWG, FW PFOS Gavage 0.1-3.75 mg/kg Rat: 6-17 GDs 
Rabbit: 6-20 GDs 
Rabbit 
• MWG: significantly lower 
• FW: significantly lower at >= 2.5 
mg/kg 
(Cassone et al. 
2012) 
Chicken  Tarsus length, Embryo mass, 
T4 
PFHxS 
PFHxA 
Injection PFHxS: 8.9-38000 
ng/g 
PFHxA: 9.7-9700 ng/g 
Single dose prior of 
incubation 
• Tarsus length: significantly lower at 
38000 ng/g PFHxS 
• Embryo mass: significantly lower at 
38000 ng/g PFHxS 
• T4: significantly lower at >=890 ng/g 
PFHxS  
(S. Chang et al. 
2018) 
Mouse GL, PW, Thyroid function PFHxS Gavage 0.3-3 mg/kg Before mating, 
gestation, lactation 
No significant association 
(S.-C. Chang et 
al. 2009) 
Rat Thyroid function (dams and 
pups) 
PFOS Gavage 0.1-1 mg/kg 0 GD-20 PND No significant association 
(J. Chen et al. 
2013) 
Zebrafish Malformations, Behavior PFOS Immersion 0.5μM 1-21 dpf 
21-120 dpf 
1-120 dpf 
• Malformations: significantly higher 
rate (uninflated swim bladder and 
curved spine) 
• Behavior: significantly higher swim 
rate  
(J. Chen et al. 
2014) 
Zebrafish Malformations PFOS Immersion 16 μM 0-48 hpf 
48-96 hpf 
Malformations: uninflated swim 
bladder, less developed gut, and 
curved spin in 48-96 hpf exposed 
group 
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(Dang, Wang, 
and Liu 2018) 
Zebrafish Body length, Malformations, 
Heart rate 
PFOS Immersion 1-10 μM 2-96 hpf • Body length: significantly lower in 
exposed groups 
• Malformations: significantly higher 
rate at 10 μM 
(Das et al. 2008) Mouse MW, FW, Malformations, 
Eye opening 
PFBA Gavage 35-350 mg/kg 1-17/35 GDs Eye opening: significantly delayed in 
exposed groups 
(Das et al. 2015) Mouse MWG, FW, Eye opening PFOA 
PFOS 
PFNA 
Gavage 1-10 mg/kg 1-17 GDs Eye opening: significantly delayed at 
>=3 mg/kg 
(Du et al. 2009) Zebrafish Malformations, Thyroid 
function 
PFOS Immersion 10-250 μgL-1 70 days (zebrafish 
fry) 
Malformations: significantly higher 
rate at 50 and 250 μgL-1 (most 
frequent: curved spine) 
(Era et al. 2009) Mouse Cleft palate PFOS Gavage 9-30 mg/kg 1-17 GDs Cleft palate: significant higher rate in 
exposed groups  
(Fuentes et al. 
2006) 
Mouse MW, FW, Thyroid function 
(dams) 
PFOS  Gavage 1.5-6 mg/kg 6-18 GDs No significant association 
(Fuentes et al. 
2007) 
Mouse Motor activity, Spatial 
learning 
at 3 month of age 
PFOS Gavage 6 mg/kg 12-18 GDs • Motor activity: significantly lower 
when considering PFOS*restrain 
• Spatial learning: significantly 
delayed learning when considering 
PFOS*restrain 
(Goulding et al. 
2017) 
Mouse Motor activity at 18,19,20 
PNDs 
PFOA Gavage 0.1-1 mg/kg 1-17 GDs Significantly higher activity at PND28 
at 1 mg/kg and subsequent decrease 
(Grasty et al. 
2003) 
Rat MWG, PW PFOS Gavage 4 GDs: 25 mg/kg 
2 GDs: 25-50 mg/kg 
4 GDs 
2 GD (19-20 GDs) 
• MWG: significantly lower 
• PW: significantly lower (in 4GDs 
exposure, before 14 GDs) 
(Hagenaars et al. 
2014) 
Zebrafish Body length, Swim activity PFOS Immersion 0.5-5 mgL-1 1-144 hpf 
 
Body length: significantly reduced 
Swim activity: significantly reduced 
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(Hagenaars et al. 
2011) 
Zebrafish Body length, Malformations, 
Heart rate 
PFOA 
PFOS 
PFBS 
PFBA 
Immersion 10-500 mgL-1 
1-100 mgL-1 
50-3000 mgL-1 
50-3000 mgL-1 
8-120 hpf • Body length: significantly lower at 
PFOS >=1 mgL-1 and PFOA >=100 
mgL-1 
• Malformations (head): PFOA and 
PFOS 
• Malformations (tail): all PFAS 
• Heart rate: significantly altered at 
the highest concentrations of PFOS, 
PFOA, PFBS 
(Hu, Strynar, and 
DeWitt 2010) 
Mouse MWG, PW PFOA Drinking 
water 
0.5-1 mg/kg 6-17 GDs No significant association 
(Huang et al. 
2010) 
Zebrafish Malformations, Heart rate, 
Swim activity 
PFOS Immersion 0.01-16.0 μM 6-120 hpf • Malformations: higher rate in 
exposed in a dose-dependent manner 
• Heart rate: significantly lower 
• Swim activity: significantly higher 
speed and swim rate in exposed 
groups 
(Iwai and 
Hoberman 2014) 
Mouse PW PFHxA Gavage 100-500 mg/kg 6-18 GDs PW: significantly lower at 350-500 
mg/kg  
(Jantzen et al. 
2016) 
Zebrafish Body length, Interoocular 
distance (proxy of cranofacial 
development), Swim activity 
PFOS 
PFOA 
PFNA 
Immersion 0.02-2 μM 3-120 hpf • Body length: significantly lower at  
>=2 μM of PFOA, PFOS, PFNA 
• Interoocular distance: significantly 
higher for PFOA (2 μM) and PFOS 
(all concentrations) 
• Swim activity: significantly lower 
speed (PFOS, PFNA), increased in 
distance travelled (PFOS, PFOA, 
PFNA) 
(Jiang et al. 2012) Chicken  Yolk-free weight, Heart 
structure and morphology 
PFOA Egg 
injection 
0.5-2 mg/kg Single dose at 
incubation day 0 
PFOA exposure associated with heart 
morphology and function alterations 
(M. Kim et al. 
2013) 
Xenopus Growth, Malformations PFOA 
PFNA 
PFDA 
PFuDA 
Immersion 130 μM  
40 μM (PFuDA) 
10 days • Growth: significantly lower in 
exposed groups 
• Malformations: exposed groups 
developed several malformations in a 
dose-dependent manner 
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(Lau et al. 2003) Rat 
Mouse 
PW, Eye opening, Thyroid 
function (pups) 
PFOS Gavage Rat: 1-10 mg/kg 
Mouse: 1-20 mg/kg 
Rat: 2-21 GDs  
Mouse: 1-17 GDs  
Rats 
• PW: significantly lower at >= 
2mg/kg 
• Eye opening: significantly delayed at 
>= 2mg/kg 
• Thyroid: T4 significantly lower 
Mice 
• Eye opening: significantly delayed in 
exposed groups 
(Lau et al. 2006) Mouse MWG, PW, Ossification PFOA Gavage 1-40 mg/kg 1-17 GDs • PW: significantly lower in 20 mg/kg 
groups 
• Ossification: significantly lower in 
10-20 mg/kg groups 
(C. K. Lee et al. 
2015) 
Mouse MWG, Placental weight, FW, 
Placental efficiency 
(FW/placental weight) 
PFOS Gavage 0.5-8 mg/kg 11-16 GDs • MWG: significantly lower at >=2 
mg/kg 
• Placental weight: significantly lower 
in exposed groups 
• FW: significantly lower in exposed 
groups 
• Placental efficiency: significantly 
lower in exposed groups 
(X. Li et al. 2016) Rat Placental weight, FW PFOS Gavage 5-20 mg/kg 12-18 GDs • Placental weight: significantly lower 
in 20mg/kg group 
• FW: significantly lower in 20mg/kg 
group 
(Luebker et al. 
2005) 
Rat PW; Eye opening PFOS Gavage 0.1-3.2 mg/kg Prior to mating-
Gestation-Lactation 
 
Eye opening: significantly delayed at 
0.4 mg/kg 
(Macon et al. 
2011) 
Mouse PW PFOA Gavage 0.3-3 mg/kg 
0.01-1 mg/kg 
1-17 GDs 
10-17 GDs 
No significant association 
(Onishchenko et 
al. 2011) 
Mouse MWG, PW, Locomotor 
activity, Circadian activity, 
Emotion-related behavior, 
Muscle strength 
PFOA 
PFOS 
Food 0.3 mg/kg 1 GD-through 
pregnancy 
• Locomotor activity: significant 
inverse association with PFOS in 
males 
• Circadian activity: significantly 
higher in males exposed to PFOA 
• Emotion-related behavior: activity 
significantly reduced in males 
exposed to PFOS 
(Peden-Adams et 
al. 2009) 
Chicken Malformations PFOS Injection 1-5 mg/kg Single dose at 
incubation day 0 
Right wing significantly shorted in 
exposed groups 
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(Pinkas et al. 
2010) 
Chicken Imprinting performance PFOA 
PFOS 
Eggs 
injection 
5-10 mg/kg Single dose at 
incubation day 0 
Lower scores in imprinting 
performance in exposed animals 
(Rogers et al. 
2014) 
Rat MWG, PW, BP (pups) PFOS 
PFNA 
Gavage PFOS: 18.75 mg/kg 
PFNA: 5 mg/kg 
PFOS: 2-6 GDs 
PFNA: 1-20 GDs 
• MWG: significantly lower in 
exposed groups 
• PW: significantly lower exposed to 
PFOS (only females) and PFNA 
BP: significantly higher in PFOS and 
PFNA exposed animals 
(X. Shi et al. 
2008) 
Zebrafish Body length, Malformations PFOS Immersion 0.1-5 mg/L 4 hpf-until 
observation 
• Body length: significantly lower at 
>=03 mg/L 
• Malformations: significantly higher 
rate in a dose-dependent manner 
(Sobolewski et al. 
2014) 
Mouse PW, Locomotor behavior, 
Novel object exploration, 
Fixed interval reinforcement 
schedule 
PFOA Gavage 0.1 mg/kg 7 GD-until weaning • Locomotor activity: significantly 
higher in exposed 
• Object exploration: significantly 
lower in exposed 
(Spachmo and 
Arukwe 2012) 
Atlantic 
salmon 
W (larvae), BL, Bone 
development 
PFOA 
PFOS 
Immersion 100 Μg/L 52 days (from egg 
stage) 
No significant association 
(Spulber et al. 
2014) 
Zebrafish Swim activity PFOS Food 0.1-1 mg/L 2 hpf-6 dpf Hyperactivity at 1 mg/L 
(Staples, Burgess, 
and Kerns 1984) 
Rat MWG, FW, Malformations PFOA Gavage 
Inhalation 
Gavage: 100 mg/kg 
Inhalation: 0.1-25 
mg/m3 
6-15 GDs Inhalation 
• MWG: significantly lower at 
25mg/m3 
• FW: significantly lower at 25mg/m3 
• Malformations (ossification): higher 
incidence at 25mg/m3 
Gavage 
• MWG: significantly lower in 
exposed 
(Suh et al. 2011) Mouse MW, Placental weight, FW PFOA Gavage 2-25 mg/kg 11-16 GDs • MW: significantly lower at >=13 
GDs 
• Placental weight: significantly lower 
at >=2 mg/kg 
• FW: significantly lower at >=10 
mg/kg 
(Thibodeaux et al. 
2003) 
Rat 
Mouse 
MWG, FW, T3 (dam), T4  
(dam), TSH  (dam) 
PFOS Gavage Rat: 1-10 mg/kg 
Mouse: 0.1-2 mg/ml 
vehicle 
Rat: 2-20 GDs 
Mouse: 1-17 GDs 
Rat 
• MWG: significantly lower at 
>=2mg/kg 
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• T3: significantly lower in exposed  
• T4: significantly lower in exposed  
• FW: significantly lower at 10mg/kg 
• Malformations: significantly higher 
incidence of skeletal abnormalities at 
10 mg/kg 
(Ulhaq et al. 
2013) 
Zebrafish Locomotor activity PFOA 
PFOS 
PFNA 
PFBA 
PFDA 
PFBS 
TFAA 
Immersion 3-1000 mg/L 
0.03-10 mg/L 
0.03-10 mg/L 
10-3000 mg/L 
0.1-30 mg/L 
10-3000 mg/L 
10-3000 mg/L 
144 hpf Changes in behavioural patterns in 
exposed to PFNA, PFBS, PFOS, 
TFAA 
(J. Wang et al. 
2010) 
Fruit fly Larvae volume, Pupae weight, 
Larvae activity 
PFOA Food 100-500 μM  Egg laying • Larvae volume: significantly lower 
at  500 μM 
• Pupae weight: significantly lower at  
500 μM 
• Larvae activity: significantly lower 
contractions at 500 μM  
(M. Wang et al. 
2011) 
Zebrafish Body length 
Malformations 
PFOS Immersion 5-250 μg/L  8 hpf-150 dpf Body length: significantly lower at 
250 μg/L  
Malformations: significantly higher 
incidence in F1 larvae from parental 
exposure at 250 μg/L 
(Yu Wang et al. 
2015) 
Rat Spatial learning, Memory  PFOS Water 5-15 mg/kg Gestation and 
lactation 
Spatial learning: escape latency 
significantly higher in exposed 
(White et al. 
2007) 
Mouse MWG, PW PFOA Gavage 5 mg/kg 1-17 GDs 
8-17 GDs 
12-17 GDs 
PW: lower in exposed following an 
exposure-duration fashion 
(White et al. 
2009) 
Mouse MWG, PW PFOA Gavage 5 mg/kg 8-17 GDs MWG: significantly higher in 
exposed  
(White et al. 
2011) 
Mouse MWG, PW PFOA Gavage 1-5 mg/kg 1-17 GDs PW: significantly lower at 5 mg/kg 
(Wolf et al. 2007) Mouse MWG, PW, Eye opening PFOA Gavage 3-5 mg/kg 1-17 GDs • PW: significantly lower at 5 mg/kg 
• Eye opening: significantly delayed in 
exposed 
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(Yahia et al. 
2010) 
Mouse MWG, FW, PW PFOA Gavage 1-10 mg/kg 0-17 GDs 
0-18 GDs 
• MWG: significantly lower at 10 
mg/kg 
• FW: significantly lower at 5-10 
mg/kg 
• PW: significantly lower at 5-10 
mg/kg 
(Yanai et al. 
2008) 
Chicken Malformations PFOA Injection 5-40 mg/kg Single dose at 
incubation day 0 
Significant higher rate of splayed leg 
and atypical pigmentation at >=20 
mg/kg 
(Yu et al. 2009) Rat T3 (pups), T4 (pups) PFOS Food 3.2 mg/kg feed Gestation, Lactation T4: significantly lower at PND 21 and 
35 
(L. Zhang et al. 
2011) 
Zebrafish Malformations PFOS Immersion 1 mg/L 6-192 hpf Significantly higher rate in a time-
dependent manner 
(Zhao et al. 2017) Chicken Cardiotoxicity PFOA Injection 2 mg/kg Single dose at 
incubation day 0 
Heart rate: significantly higher 
ROS and NOS: significantly higher at 
ED19 
(Zheng et al. 
2011) 
Zebrafish Malformations PFOA 
PFOS 
PFNA 
Immersion 150-270 mg/L 
6.25-200 mg/L 
6.25-200 mg/L 
4-96 hpf Malformations: higher rate incidence 
at >=72 hpf 
GL (gestational length); MW (maternal weight); MWG (maternal weight gain); PW (pups’ weight); FW (fetal weight); GD (gestational day); PND (postnatal day); ED (embryonic day), 
HPF (hours post fertilization); BP (blood pressure); ROS (reactive oxygen species); NO (nitric oxide) 
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Table 5. Human evidence included in the review. Significant adverse effects are in bold. 
Author, 
Year Outcome/s Exposure Matrix Study design Setting Population Results 
(Alkhalawi 
et al. 2016) 
BW, BL, PI PFOA 
PFOS 
PFHxS 
Maternal 
blood 
Cohort study 
(DBCS) 
Duisburg 
(Germany) 
156 mother–child 
pairs 
PI: significant inverse association with PFOA 
and PFOS  
(Andersen et 
al. 2010) 
BW, BL PFOA 
PFOS 
Maternal 
blood 
Cohort study 
(DNBC) 
Denmark 1144 mother–
child pairs  
BW: significant inverse association with 
PFOA  
(Antignac et 
al. 2013) 
BW PFOA 
PFOS 
PFHxS 
Breast 
milk 
Retrospective 
study (ELFE) 
France 48 breast milk 
samples 
No significant association 
(Apelberg et 
al. 2007) 
GA, BW, BL, HC, PI  PFOA 
PFOS 
Cord 
blood 
Cross-sectional Baltimore, 
Maryland (USA) 
293 mother-child 
pairs 
• BW: significant inverse association with 
PFOA and PFOS adjusted for GA 
• HC: significant inverse association with 
PFOA and PFOS 
• PI: significant inverse association with 
PFOA and PFOS 
(Arbuckle et 
al. 2013) 
LBW (<2500g) PFOA 
PFOS 
PFNA 
PFHxS 
Cord 
blood 
Cohort study Ottawa (Canada) 100 mother-child 
pairs 
Weak association with PFOA  
(Ashley-
Martin et al. 
2016) 
GWG PFOA 
PFOS 
PFHxS 
Maternal 
blood 
Cord 
blood 
Cohort study 
(MIREC) 
Canada 1723 woman 
(maternal blood) 
1301 woman 
(cord blood) 
Significant positive association with PFOA 
and PFOS 
(Ashley-
Martin et al. 
2017) 
BW PFOA 
PFOS 
PFHxS 
Maternal 
blood 
Cohort study 
(MIREC) 
Canada 1705 mother-
child pairs 
Weak inverse association of PFOA with BW 
z-score 
(Bach et al. 
2016) 
BW (continuous and z-
score), BL, HC 
PFOA 
PFOS 
PFHxS 
PFHpS 
PFNA 
PFDA 
PFUnA  
Maternal 
blood 
Cohort study 
(Aarhus) 
Aarhus 
(Denmark) 
1507 mother-
child pairs 
BW: weak inverse association with PFHxS, 
PFHpS, PFOS 
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(Berg et al. 
2015) 
TSH, T3, T4, TH-BPs 
(mother) 
PFOA 
PFOS 
PFHxS 
PFHpS 
PFNA 
PFDA 
PFUnDA 
Maternal 
blood  
Cohort study 
(MISA) 
Northern 
Norway 
391 pregnant 
women 
• TSH: significant positive association with 
PFOS 
• T3: significant inverse association with 
PFDA 
• FT3: significant inverse association with 
PFUnDA 
only for highest quartiles 
(Berg et al. 
2017) 
T3 (mother), T4 
(mother), TSH (mother 
and child) 
PFOA 
PFOS 
PFHxS 
PFHpS 
PFDA 
PFUnDA 
Maternal 
blood 
Cohort study 
(MISA) 
Norway 391 mother-child 
pairs 
T3: significant inverse association with PFDA, 
PFUnDA  
TSH: significant direct association with 
PFOS, PFHxS, PFHpS 
(Braun et al. 
2014) 
Social Responsiveness 
Scale (SRS) 
PFOA 
PFOS 
PFNA 
PFHxS 
Maternal 
blood and 
Maternal 
urine 
Cohort study 
(HOME) 
Cincinnati, Ohio 
(US) 
222 mother-child 
pairs 
No significant association 
(Callan et al. 
2016) 
BW, BL, HC PFOA 
PFOS 
PFHxS 
PFHpA 
PFNA 
PFDA 
PFUnDA 
Maternal 
blood 
Cross-sectional 
(AMETS) 
Western 
Australia 
98 mother-child 
pairs 
Proportion of optimal BW: significant 
positive association with PFUnDA, significant 
inverse association with PFHxS 
(Cao et al. 
2018) 
BW, BL, HC PFOA 
PFOS 
PFNA 
PFDA 
PFUdA 
PFDoA 
PFTrDA 
PFTeDA 
PFHxDA 
PFHxS 
Cord 
blood 
Cohort study Zhoukou 
(China) 
337 mother-child 
pairs 
• BW: significant inverse association with 
PFDoA 
• BL: significant inverse association with 
PFOA and PFHxS 
(Chan et al. 
2011) 
T4 (mother) PFOA 
PFOS 
PFHxS 
Maternal 
blood 
Case-control 
study 
Edmonton, 
Alberta 
(Canada) 
Pregnant women 
(96 cases-175 
controls) 
No significant association 
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(M.-H. Chen 
et al. 2012) 
GA, BW, BL, HC, PI, 
PB, LBW (<2500G), 
SGA (<10th percentile) 
PFOA 
PFOS 
PFNA 
PFuDA 
Cord 
blood 
Cohort study 
(TBPS) 
Taiwan 428 mother-child 
pairs 
• GA: significant inverse association with 
PFOS 
• BW: significant inverse association with 
PFOS 
• HC: significant inverse association with 
PFOS 
• SGA: significant higher odds (PFOS) 
(M.-H. Chen 
et al. 2013) 
Comprehensive 
Developmental inventory 
for infants and Toddlers  
at 2 years of age 
PFOA 
PFOS 
Cord 
blood 
Cohort study 
(TBPS) 
Taiwan 239 mother-child 
pairs 
Significant inverse association with PFOS 
(whole test and gross motor subscale) 
(M.-H. Chen 
et al. 2017) 
BW, BL, BMI PFOA 
PFOS 
Cord 
blood 
Cohort study 
(TBPS) 
Taiwan 429 mother-child 
pairs 
• BW: significant inverse association with 
PFOS 
• BL: significant inverse association with 
PFOS 
• BMI: significant inverse association with 
PFOS (only at crude analysis) 
(Darrow, 
Stein, and 
Steenland 
2013) 
PB, LBW (<2500g), BW, 
PIH 
PFOA 
PFOS 
Maternal 
blood 
Population-
based study (C8 
Health Project) 
Ohio and West 
Virginia (USA) 
1630 birth 
1330 women 
• BW: modest inverse association with PFOS 
• PIH: significant positive association with 
PFOA and PFOS 
(de Cock et 
al. 2014) 
T4 (child) PFOA 
PFOS 
Cord 
blood 
Breast 
milk 
Cohort study 
(LINC) 
Netherlands 83 mother-child 
pairs 
• Females: significant positive association with 
PFOA at the highest quartile  
• Males: significant inverse association with 
PFOS at first and second quartiles (crude 
analysis) 
(de Cock et 
al. 2016) 
BW PFOA 
PFOS 
Cord 
blood 
Cohort study Zwolle (The 
Netherlands) 
91 mother-child 
pairs 
No significant association 
(Donauer et 
al. 2015) 
Neonatal Intensive Care 
Unit Network 
Neurobehavioral Scale 
(NNNS) at 5 week of age 
PFOA 
PFOS 
Maternal 
blood 
Cohort study 
(HOME) 
Cincinnati 
(Ohio) 
349 mother-child 
pairs 
Hypotonia: significant higher risk for PFOA 
(Fei et al. 
2007) 
GA, BW, LBW 
(<2500g), SGA (<10th 
percentile), PB 
PFOA 
PFOS 
Maternal 
blood 
Cohort study 
(DNBC) 
Denmark 1400 mother-
child pairs 
BW: significant inverse association with 
PFOA 
(Fei, 
McLaughlin, 
Lipworth, et 
al. 2008) 
Developmental 
milestones  
at 6 and 18 months of age 
PFOA 
PFOS 
Maternal 
blood 
Cohort study 
(DNBC) 
Denmark 1400 mother-
child pairs 
No significant association 
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(Fei, 
McLaughlin, 
Tarone, et 
al. 2008) 
PW, BL, HC, AC, PI PFOA 
PFOS 
Maternal 
blood 
Cohort study 
(DNBC) 
Denmark 1400 mother-
child pairs 
• BL: significant inverse association with 
PFOA 
• AC: significant inverse association with 
PFOA 
(Fei and 
Olsen 2011) 
Strengths and Difficulties 
Questionnaire (SDQ) 
Developmental 
Cordination Disorder 
Questionnaire (DCDQ) 
at 7 years of age 
PFOA 
PFOS 
Maternal 
blood 
Cohort study 
(DNBC) 
Denmark 787 mother-child 
pairs 
No significant association 
(Forns et al. 
2015) 
Ages and Stages 
Questionnaire (ASQ-II) 
at 6 and 24 month of age 
Infant/Toddler Symptoms 
Checklist 
(ITSC) at 12 and 24 
month of age 
PFOA 
PFOS 
Breast 
milk 
Cohort study 
(HUMIS) 
Norway 843 mother-child 
pairs 
No significant association 
(Goudarzi et 
al. 2016) 
Bayley Scales of Infant 
Development (BSID II) 
Mental Developmental 
Index (MDI) 
Psychomotor 
Developmental Index 
(PDI) 
at 6 and 18 month of age 
PFOA 
PFOS 
Maternal 
blood 
Cohort study 
(Hokkaido) 
Hokkaido 
(Japan) 
173 mother-child 
pairs (6-month) 
133 mother-child 
pairs (18-month) 
Significant inverse association with MDI 
scores at 6-month of age in females 
(Govarts et 
al. 2018) 
SGA (<10th percentile) PFOA 
PFOS 
Cord 
blood 
(measured 
or 
estimated) 
FLEHS I 
FLEHS II 
HUMIS 
INMA cord 
INMA mat 
LINC 
PCB 
PELAGIE 
pooled analysis 
of birth cohorts 
(OBELIX birth 
cohorts) 
Belgium 
Belgium 
Norway 
Spain 
Spain 
The Netherlands 
Slovakia 
France 
1105 
242 
440 
1287 
860 
84 
1034 
394 
OBELIX birth 
cohorts: 5446 
mother-child 
pairs (subset of 
693 for PFAS) 
Significant higher odds of SGA for PFOA and 
PFOS in smokers  
(Govarts et 
al. 2016) 
BW PFOA 
PFOS 
Cord 
blood 
Cohort study 
(FLEHS II) 
Flanders 
(Belgium) 
248 mother-child 
pairs 
No significant association 
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(Gyllenham
mar et al. 
2018) 
GL, BW, BL, HC PFOA 
PFOS 
PFHxS 
PFNA 
PFBS 
PFUnDA 
Maternal 
blood 
Cohort study 
(POPUP) 
Sweden 381 mother-child 
pairs 
No significant association 
(Hamm et 
al. 2010) 
GA, BW, SGA (<10th 
percentile), PB 
PFOA 
PFOS 
PFHxS 
Maternal 
blood 
Cohort study Edmonton, 
Alberta 
(Canada) 
52 mother-child 
pairs 
SGA: protective role of PFOS 
(Harris et al. 
2018) 
Peabody Picture 
Vocabulary Test (PPVT-
III) 
Wide Range Assessment 
of Visual Motor Abilities 
(WRAVMA)  
Kaufman Brief 
Intelligence Test (KBIT-
2) 
Visual Memory Index of 
the Wide Range 
Assessment of Memory 
and Learning 
(WRAML2) 
in early (3 years) and mid 
(7 years) childhood 
PFOA 
PFOS 
PFHxS 
Maternal 
blood 
Cohort study 
(Project Viva) 
Massachusetts 
(USA) 
986 (early 
childhood) 
865 (mid-
childhood) 
Weak inverse association of visual-motor 
scores with PFOA and PFOS in mid-
childhood 
(Høyer et al. 
2015) 
Developmental 
Coordination Disorder 
Questionnaire 2007 
(DCDQ) and Strength 
and Difficulties 
Questionnaire (SDQ) 
at 5-9 years of age 
PFOA 
PFOS 
Maternal 
blood 
Cohort study 
(INUENDO) 
Greenland, 
Poland, Ukraine 
1016 mother-
child pairs 
Significant higher risk of hyperactivity for 
PFOA 
(Jaacks et al. 
2016) 
GWG PFOA 
PFOS 
PFOSA 
PFNA 
PFDeA 
Maternal 
blood 
Cohort study 
(LIFE) 
Michigan and 
Texas (USA) 
218 pregnant 
women 
Significant positive association of PFOS with 
GWG AUC in normal weight women 
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Et-PFOSA-
AcOH 
Me-PFOSA- 
(Jeddy et al. 
2017) 
Communication 
development 
at 15 and 38 months of 
age 
PFOA 
PFOS 
PFHxS 
PFNA 
Maternal 
blood 
Cohort study 
(ALSPAC)  
Avon (Great 
Britain) 
432 mother-child 
pairs (females) 
Inconsistent associations  
(Kato et al. 
2016) 
T4, TSH (mother and 
child) 
PFOA 
PFOS 
Maternal 
blood 
Cohort study 
(Hokkaido) 
Hokkaido 
(Japan) 
392 mother-child 
pairs 
Mother 
• TSH: significant inverse association with 
PFOS 
• T4: significant inverse association with 
PFOS 
Child 
• TSH: significant positive association with 
PFOS 
(S. Kim et 
al. 2011) 
T3, T4, TSH (cord 
blood), BW 
PFOA 
PFOS 
PFHxS 
PFHpS 
PFNA 
PFDA 
PFUnDA 
PFTrDA 
Maternal 
blood 
Cord 
blood 
Cross-sectional Seoul, 
Cheongju, Gumi 
(South Korea) 
35 mother-child 
pairs (including 4 
pairs of twins) 
• T3: significant inverse association with 
maternal PFOS and PFTrDA 
• T4: significant inverse association with 
maternal PFTrDA 
• TSH: significant positive association with 
maternal PFOA 
(Kishi et al. 
2015) 
Maternal FAs and TG, 
BW 
PFOA 
PFOS 
Maternal 
blood 
Cohort study 
(Hokkaido) 
Hokkaido 
(Japan) 
306 mother-child 
pairs 
• FAs: significant inverse association with 
PFOS 
• TG: significant inverse association with 
PFOS 
• BW: significant inverse association with 
PFOS in females 
(Kobayashi 
et al. 2017) 
DNA methylation (IGF2, 
H19, LINE1) and its 
association with BW, 
HC, PI 
PFOA 
PFOS 
Maternal 
blood 
Cohort study 
(Hokkaido) 
Hokkaido 
(Japan) 
177 mother-child 
pairs 
IGF2 methylation: significant inverse 
association with PFOA 
explaining ~ 21% of the association between 
PFOA and PI (even if not significant) 
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(Kwon et al. 
2016) 
BW PFOA 
PFOS 
PFHxS 
PFNA 
PFDA 
PFUnDA 
PFDoDA 
PFTrDA 
Cord 
blood 
Cohort study 
(EBGRC) 
Seoul (Korea) 268 mother-child 
pairs 
BW: significant inverse association with 
PFOA, PFOS, PFNA, PFDA, PFUnDA  
(Lauritzen et 
al. 2017) 
GA, BW, BL, HC, SGA 
(<10th percentile) 
PFOA 
PFOS 
Maternal 
blood 
Cohort study 
(NICHD)  
Norway and 
Sweden 
424 mother-child 
pairs 
Sweden cohort 
• BW: significant inverse association with 
PFOS 
• BL: significant inverse association with 
PFOA and PFOS 
• SGA: significant higher odds (PFOA) 
(E.-S. Lee, 
Han, and Oh 
2016) 
BW PFOA 
PFOS 
PFHxS 
PFNA 
PFDA 
PFUnA 
PFDoA 
Cord 
blood 
Cross-sectional Seoul (South 
Korea) 
85 mother-child 
pairs 
No significant association 
(Y. J. Lee et 
al. 2013) 
BW, BL, HC, PI PFOA 
PFOS 
PFHxS 
Cord 
blood 
Cross-sectional Gyeongbuk 
county (South 
Korea) 
59 mother-child 
pairs 
• BW: significant inverse association with 
PFHxS 
• BL: significant inverse association with 
PFHxS 
• PI: significant inverse association with 
PFOS 
(Lenters et 
al. 2016) 
BW PFOA 
PFOS 
PFHxS 
PFHpA 
PFNA 
PFDA 
PFUnDA 
PFDoDA 
Maternal 
blood 
Cohort study 
(INUENDO) 
Greenland, 
Poland, Ukraine 
1250 mother-
child pairs 
Significant inverse association with PFOA 
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(M. Li et al. 
2017) 
GA, BW, PB, LBW 
(<2500g) 
PFOA 
PFOS 
PFHxS 
PFNA 
PFDA 
PFUnDA 
PFHpA 
PFBA 
PFDoDA 
isomers of 
PFOA and 
PFOS 
Cord 
blood 
Cohort study 
(GBCS) 
Guangzhou 
(China) 
321 mother-child 
pairs 
BW: significant inverse association with 
PFOA, PFOS, and their isomers 
(Lien et al. 
2016) 
ADHD at 7 years of age PFOA 
PFOS 
PFNA 
PFuDA 
Cord 
blood 
Cohort study 
(TBPS and TEC) 
Taiwan 282 mother-child 
pairs 
Significant inverse association of inattention 
with PFNA 
(Liew et al. 
2014) 
Congenital cerebral plasy PFOA 
PFOS 
PFHxS 
PFNA 
PFHpS 
PFDA 
Maternal 
blood 
Case-control 
study based on 
DNBC cohort 
Denmark 156 cases-550 
controls 
Significant positive association with PFOA 
and PFOS in boys 
(Liew et al. 
2015) 
ADHD and Autism PFOA 
PFOS 
PFHxS 
PFHpS 
PFNA 
PFDA 
Maternal 
blood 
Case-control 
study based on 
DNBC cohort 
Denmark 220 ADHD 
220 Autism 
550 Controls 
No significant (or consistent) association 
(Maekawa et 
al. 2017) 
BW, PW PFOA 
PFOS 
PFHxS 
PFNA 
Maternal 
blood 
Cord 
blood 
Cross-sectional Yamaguchi 
(Japan) 
145 pregnant 
women  
• BW: significant inverse association with 
PFNA 
• PW: significant inverse association with 
PFNA 
analyses not adjusted by potential 
confounders 
(Maisonet et 
al. 2012) 
GA, BW, BL, PI PFOA 
PFOS 
PFHxS 
Maternal 
blood 
Cohort study 
(ALSPAC) 
Avon (Great 
Britain) 
447 mother-child 
pairs (females) 
• BW: significant inverse association with 
PFOA, PFOS, PFHxS 
• BL: significant inverse association with 
PFOS and PFHxS 
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(Manzano-
Salgado et 
al. 2017) 
GA, BW, BL, HC, SGA 
(<10th percentile), LBW 
(<2500g) (+ modifying 
effect of GFR) 
PFOA 
PFOS 
PFHxS 
PFNA 
Maternal 
blood 
Cohort study 
(INMA) 
Spanish 1202 mother-
child pairs 
No significant association 
(Matilla-
Santander et 
al. 2017) 
IGT, GDM, Cholesterol, 
TG, CRP 
PFOA 
PFOS 
PFHxS 
PFNA 
Maternal 
blood 
Cohort study 
(INMA) 
Spain 1240 pregnant 
women 
• IGT: significant positive association with 
PFOA, PFOS, PFHxS 
• GDM:  significant positive association with 
PFOA, PFOS, PFHxS 
• TG: significant inverse association with 
PFOS and PFNA 
(Minatoya et 
al. 2017) 
BW, PI, leptin and 
adiponectin in cord blood  
PFOA 
PFOS 
Maternal 
blood 
Cohort study 
(Hokkaido) 
Hokkaido 
(Japan) 
168 mother-child 
pairs 
• BW: significant inverse association with 
PFOA 
• PI: significant inverse association with 
PFOS  
• Adiponectin: significant positive association 
with PFOS 
(Monroy et 
al. 2008) 
BW PFOA 
PFOS 
PFDeA 
PFHxS 
PFHpA 
PFNA 
Maternal 
blood 
Cord 
blood 
Cohort study 
(Family Study) 
Canada 101 pregnant 
women 
105 cord blood 
samples 
No significant association 
(Nolan et al. 
2009) 
BW, PB, LBW (<2500g) Maternal 
residing as 
proxy of 
expsoure to 
PFOA 
NA Cross-sectional  Ohio (USA) 1555 newborns No significant association 
(Nolan et al. 
2010) 
Congenital anomalies, 
labor/delivery 
complications 
Maternal 
residing as 
proxy of 
expsoure to 
PFOA 
NA Cross-sectional  Ohio (USA) 1548 newborns Labor/delivery compl.: significant positive 
association with contaminated water service 
(Ode et al. 
2014) 
ADHD PFOA 
PFOS 
PFNA 
Cord 
blood 
Case-control 
study 
Malmo, Sweden 206 cases-206 
controls 
No significant association 
(Oulhote et 
al. 2016) 
Strengths and Difficulties 
Questionnaire (SDQ)  
at 7 years of age 
PFOA 
PFOS 
PFHxS 
PFNA 
PFDA 
Maternal 
blood 
Cohort study Faroe Islands 539 mother-child 
pairs 
No significant association 
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(Preston et 
al. 2018) 
TSH (mother) 
T4 (mother and child) 
T3 (mother) 
T3U (mother) 
PFOA 
PFOS 
PFHxS 
PFNA 
Maternal 
blood 
Cohort study 
(Project Viva) 
Massachusetts 
(USA) 
732 mother-child 
pairs 
Mother 
FT4I: significant inverse association with 
PFOA 
Child 
T4: significant inverse association with 
PFHxS in males 
(Quaak et al. 
2016) 
Behavioral development  
at 18 months of age 
PFOA 
PFOS 
PFHxS 
PFNA 
PFDA 
PFHpS 
PFUnDA 
Cord 
blood 
Cohort study 
(LINC) 
Netherlands 59 mother-child 
pairs 
Significant inverse association of PFOA with 
externalizing behavior in males 
(Rokoff et 
al. 2018) 
BW/GA z-score PFOA 
PFOS 
PFHxS 
PFNA 
Maternal 
blood 
Cohort study 
(Project Viva) 
Massachusetts 
(USA) 
1597 mother-
child pairs 
Significant inverse association with PFNA 
(Savitz, 
Stein, 
Elston, et al. 
2012) 
PIH, PB, LBW (<2500g), 
SGA (<10th percentile) 
Retrospective 
estimation of 
PFOA 
Maternal 
blood 
Retrospective 
study 
Ohio and West 
Virginia (USA) 
8253 births No significant association  
(Savitz, 
Stein, 
Bartell, et al. 
2012) 
Preeclampsia, PB, LBW 
(<2500g), birth defects 
Retrospective 
estimation of 
PFOA 
Maternal 
blood 
Retrospective 
study based on 
C8 Health 
Project 
Ohio and West 
Virginia (USA) 
11737 
pregnancies 
No significant association (only weak for 
preeclampsia) 
(Shah-
Kulkarni et 
al. 2016) 
T3, T4, TSH (cord blood) PFOA 
PFOS 
PFNA 
PFDoDA 
PFTrDA 
PFTeDA 
PFPeA 
PFUnDA 
PFHxS 
Cord 
blood 
Cohort study 
(EBGRC) 
Seoul (Korea) 279 mother-child 
pairs 
• T3: significant positive association with 
PFDA (overall); significant inverse 
association with PFPeA (males); significant 
positive association with PFHxS (females) 
• T4: significant positive association with 
PFPeA (overall and females) 
• TSH: significant inverse association with 
PFNA in girls 
(Y. Shi et al. 
2017) 
GA, BW, BL, PI PFOA 
PFOS 
PFHxS 
PFNA 
PFDA 
PFUna 
Cord 
blood 
Cross-sectional Beijing (China) 170 newborns No significant association 
51 
 
(Skuladottir 
et al. 2015) 
Cholesterol (+ modifying 
effect of diet) 
PFOA 
PFOS 
Maternal 
blood 
Cohort study Aarhus 
(Denmark) 
854 pregnant 
women 
• Cholesterol: significant positive association 
with PFOA and PFOS 
• Diet: predictor of PFOA and PFOS but not 
modifying the association with cholesterol 
(Starling et 
al. 2017) 
BW, body adiposity (+ 
modifying effect of 
maternal gluose and 
lipids) 
PFOA 
PFOS 
PFNA 
PFDeA 
PFHxS 
Maternal 
blood 
Cohort study 
(Healthy Start) 
Colorado (USA) 628 mother-child 
pairs 
• BW: significant inverse association with 
PFOA and PFNA 
• Maternal glucose: significant inverse 
association with PFOA, PFNA, PFDeA 
~10% of the effect of PFAS on neonatal 
adiposity mediated by  glucose 
(Starling et 
al. 2014) 
Preeclampsia PFOA 
PFOS 
PFNA 
PFUnDA 
PFHxS 
PFHpS 
Maternal 
blood 
Cohort study 
(MoBa) 
Norway 976 pregnant 
women 
No significant association 
(Stein, 
Savitz, and 
Dougan 
2009) 
Preeclampsia, PB, LBW 
(<2500g), birth defects 
PFOA 
PFOS 
Maternal 
blood 
Retrospective 
study (C8 Health 
Project) 
Ohio and West 
Virginia (USA) 
1845 pregnant 
women (PFOA) 
5262 pregnant 
women (PFOS) 
• LBW: weak association with PFOS 
• Preeclampsia: weak association with PFOS 
and PFOA 
• Birth defects: weak association with PFOA 
(Stein, 
Savitz, and 
Bellinger 
2013) 
Wechsler Abbreviated 
Scale of Intelligence 
NEPSY-II  
Connors' Continuous 
Performance Test-II  
at 6-12 years of age 
PFOA Estimated 
in utero 
PFOA 
Retrospective 
study (C8 Health 
Project) 
Ohio and West 
Virginia (USA) 
320 children No suggestive association 
(Strøm et al. 
2014) 
ADHD, Depression, 
Scholastic achievement 
until 20 years of age 
PFOA 
PFOS 
Maternal 
blood 
Cohort study Aarhus 
(Denmark) 
876 mother-child 
pairs 
No significant association 
(Vuong et 
al. 2016) 
Behavior Rating 
Inventory of Executive 
Function (BRIEF) 
PFOA 
PFOS 
PFHxS 
PFNA 
PFDeA 
maternal 
blood 
Cohort study 
(HOME) 
Cincinnati, Ohio 
(U.S.A) 
256 mother-child 
pairs 
PFOS significantly associated with lower 
BRIEF score 
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(Yan Wang 
et al. 2016) 
BW, BL, HC, SGA 
(<10th percentile) 
PFOA 
PFNA 
PFDeA 
PFUnDA 
PFDoDA 
Maternal 
blood 
Cohort study 
(TMICS) 
Taiwan 223 mother-child 
pairs 
• BW: significant inverse association with 
PFNA, PFDeA, PFUnDA, PFDoDA 
• HC: significant inverse association with 
PFDoDA 
• SGA: significant inverse association with 
PFUnDA, PFDeA 
in females 
(Yan Wang 
et al. 2014) 
T3, T4, TSH (mother and 
blood cord) 
PFOA 
PFOS 
PFHxS 
PFNA 
PFDeA 
PFUnDA 
PFDoDA 
PFHpA 
PFHxA 
Maternal 
blood 
Cohort study 
(TMICS) 
Taiwan 285 mother-child 
pairs 
Mother 
• FT4/TT4: significant inverse association 
with PFNA, PFUnDA, PFDoDA 
• T3: significant positive association with 
PFDeA 
• TSH: significant positive association with 
PFHxS 
Child 
• TT4: significant inverse association with 
PFNA, PFUnDA, PFDoDA 
• TT3: significant inverse association with 
PFNA, PFDeA, PFUnDA, PFDoDA 
(Yan Wang 
et al. 2013) 
TSH (mother) PFOA 
PFOS 
PFHpA 
PFNA 
PFDA 
PFDoDA 
PFTrDA 
PFTeDA 
PFBA 
PFHxS 
PFOSA 
Maternal 
blood 
Cross-sectional 
based on MoBA 
cohort 
Norway 903 pregnant 
women 
Weak significant positive association with 
PFOS 
(Washino et 
al. 2009) 
BW, BL, HC, CC PFOA 
PFOS 
Maternal 
blood 
Cohort study 
(Hokkaido) 
Hokkaido 
(Japan) 
428 mother-child 
pairs 
BW: significant inverse association with 
PFOS 
(Webster et 
al. 2014) 
T4, TSH PFOA 
PFOS 
PFNA 
PFHxS 
Maternal 
blood 
Cohort study 
(CHirP) 
Vancouver 
(Canada) 
152 pregnant 
women 
TSH: significant positive association with 
PFOA, PFOS, PFNA in high TPOAb women 
(Whitworth 
et al. 2012) 
BW z-score, PB, SGA 
(<10th percentile), LGA 
(>90 percentile) 
PFOA 
PFOS 
Maternal 
blood 
Cohort study 
(MoBa) 
Norway 950 mother-child 
pairs 
No significant association 
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(Wu et al. 
2012) 
GA, BW, BL, PI PFOA Maternal 
blood 
Case-control 
study 
Guangdong 
(China) 
108 cases 
(exposed)-59 
controls 
(unexposed) 
• GA: significant inverse association with 
PFOA 
• BW: significant inverse association with 
PFOA 
• BL: significant inverse association with 
PFOA 
(Yang et al. 
2016) 
T3, T4, TSH (mother) PFOA 
PFOS 
PFHxS 
PFNA 
PFDA 
PFUnA 
PFDoA 
Maternal 
blood 
Cord 
blood 
Cross-sectional Beijing (China) 157 mother-child 
pairs 
Maternal blood 
• TSH: significant inverse association with 
PFNA, PFDA, PFUnA, PFDoA, PFOS 
• FT3/T3: significant inverse association with 
PFDoA  
Cord blood 
T3/FT3: significant inverse association with 
all PFAS  
(C. Zhang et 
al. 2015) 
GDM PFOA 
PFOS 
PFNA 
PFOSA 
PFDeA 
Maternal 
blood 
Cohort study 
(LIFE) 
Michigan and 
Texas (USA) 
272 pregnant 
women 
Significant positive association with PFOA 
BW (birth weight); LBW (low birth weight); BL (birth length); HC (head circumference); AC (abdominal circumference); CC (chest circumference); PI (ponderal index); SGA (small for 
gestational age); LGA (large for gestational age); BMI (body mass index); PW (placental weight); GA (gestational age); PB (preterm birth); GWG (gestational weight gain); FAs (fatty 
acids); TG (triglyceride); FGR (fetal growth restrictions); IGT (impaired glucose tolerance); GDM (gestational diabetes mellitus); CRP (C-reactive protein); GFR (glomerular filtration 
rate); attention deficit hyperactivity disorder (ADHD) 
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Figure 1. Flow-chart of the study selection procedure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Records screened (title/abstract) 
(n = 1096) 
Records identified through database 
searching  
(n = 1096) 
Records excluded   
(n = 791) 
Full-text articles assessed for 
eligibility  
(n = 305) 
Full-text articles excluded  
(n = 166). Reasons for exclusion: 
• 15: topic 
• 136: outcome 
• 15: study population 
 
Studies included  
(n = 139) 
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Pregnancy complications in women living in an area contaminated by PFAS in Veneto Region: 
preliminary results 
1. Introduction 
Perfluoroalkylated substances (PFAS) have been extensively produced for a long time (since the mid 
of the 20th century), but only at the beginning of the 21st century it has been discovered that they are 
persistent organic pollutants and that they bioaccumulate in the fish, wildlife, and humans (U.S. 
Environmental Protection Agency 2016a, 2016b). Given such characteristics, they are ubiquitous. 
This is testified by the fact that low concentrations of PFAS were detected in the blood of more than 
98% of the U.S. general population. In the National Health and Nutrition Examination Survey 
(NHANES) 2003-2004, the median concentrations of blood perfluorooctane sulfonate (PFOS) and 
Perfluorooctanoic acid (PFOA), which were the most widely produced PFAS, were 21.1 μg/L and 4 
μg/L, respectively (Calafat et al. 2007).  
Besides the fact that the general population has been found to be exposed to background levels of 
PFAS, in recent years have been identified highly-exposed communities living in several areas around 
the world massively contaminated by PFAS. The median PFOA concentration in the residents of the 
mid-Ohio valley, an area contaminated by PFAS dramatically, was found to be 28.2 μg/L in 2005-
2006 (Steenland et al. 2009), seven times higher than that of the general population with low 
background exposure to PFAS (Calafat et al. 2007).   
The population living in geographical areas contaminated by PFAS is exposed to these chemicals 
mainly through the ingestion of contaminated drinking water and food (U.S. Environmental 
Protection Agency 2016a, 2016b). The analysis of PFAS distribution in the human body has shown 
that they distribute through the binding with serum albumin (Pérez et al. 2013) and several studies 
have been done to understand if PFAS exposure affects the function of PFAS’ target organs, focusing 
particularly on the liver (especially for what concern lipid metabolism) and the kidneys function. 
PFAS exposure has been found to be associated with higher concentrations of total and LDL 
cholesterol (Eriksen et al. 2013; Fu et al. 2014), while there is limited evidence of an association 
between PFAS exposure and type 2 diabetes (Lind and Lind 2018). Not least, PFAS exposure seems 
to be associated with higher uric acid (a marker of reduced kidney function) (Gleason, Post, and 
Fagliano 2015; Shankar, Xiao, and Ducatman 2011; Steenland et al. 2010), which is, in turn, a risk 
factor for hypertension (Feig 2014). Such studies were conducted mainly on workers, highly exposed 
communities, and the general population, while only a few studies in this field were done in pregnant 
women, with inconsistent findings. This research topic deserves further attention since liver and 
kidneys dysfunction is involved in the pathophysiology of pregnancy-induced hypertension, 
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preeclampsia, and of gestational diabetes mellitus (GDM), which affect the health of the woman and 
the fetus dramatically.  
The present work is aimed at presenting the preliminary results of a study aimed at assessing the 
epidemiology of GDM and preeclampsia in pregnant women living in an area contaminated by PFAS 
in Veneto Region, Italy. 
2. Materials and Methods 
Retrospective study on pregnant women suffering from preeclampsia or GDM who gave birth to a 
live birth or a stillbirth (2009-2015), living in the area of Veneto Region contaminated by PFAS.  
For the present work, a case of GDM was defined as a hospital admission with a diagnosis of GDM 
in the nine months before the delivery or at time of the delivery. A case of preeclampsia was defined 
as a hospital admission with a diagnosis of preeclampsia in the nine months before the delivery or at 
time of the delivery.  
In the present work, we present the preliminary data (frequencies of preeclampsia and GDM derived 
from the hospital discharge records) because a medical chart review of pregnant women hospitalized 
is ongoing to validate the cases of preeclampsia and GDM identified from the hospital discharge 
records. The choice of revising the medical charts is motivated by the fact that the use of multi-source 
approaches is considered the most reliable method for the identification of the cases of interest, 
especially if these approaches include medical charts (Lipscombe et al. 2018). The accuracy of 
hospitalization data has been shown to depend on the severity of the disease (the most severe forms 
of diabetes and preeclampsia and those associated with complications are more likely to be reported) 
and on the presence of concomitant chronic diseases not related to pregnancy (diabetes mellitus and 
chronic hypertension) (Roberts et al. 2008). Using only hospital discharge records would provide 
biased estimates, overestimating the most severe forms of the pathological conditions of interest and 
underestimating the less severe and chronic ones (Roberts et al. 2008; Abell, Zoungas, and Teede 
2017). 
2.1 Exposure 
An indirect measure of exposure to PFAS, defined as a pregnant woman’s residence in the 
contaminated area, was used. The area extends for about 200 km2 mainly in the province of Vicenza 
and, to a lesser extent, in those of Verona and Padova. The contamination was discovered in 2013 
and it involved drinking water, surface water, and ground water. It was caused by the wastewater and 
the water from the waste-water treatment of a chemical plant located in the contaminated area (WHO 
2017). Immediately after the discovery of the contamination, appropriate interventions were made to 
contain the drinking water contamination through the application of carbon filters (in the summer of 
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2013 (WHO 2017)). The analysis of drinking water showed that such intervention resulted in the drop 
of drinking water concentrations of both PFOA (from 1,475 ng/L to 386 ng/L) and PFOS (from 117 
ng/L to 36 ng/L) within three months from filters’ application (WHO 2017). However, it has been 
estimated that the contamination had lasted about 50 years (starting from the 60s), leading to long-
term exposure of the population living in the contaminated area (Dell’Acqua and Mazzola 2017). 
The residence was identified from the Veneto Region Birth Registry, a compulsory, web-based, data 
collection system of all births (including stillbirth) in Veneto Region (reporting woman residence). 
The contaminated area was identified according to an official resolution of the Veneto Region 
(Deliberazione della Giunta Regionale n. 2133 del 23 dicembre 2016, n.d.) and it includes 21 
municipalities located in the southwest of the Veneto Region. According to the Veneto Region 
resolution, the contaminated area includes all that municipalities that presented higher concentrations 
of PFAS in the drinking water than those established by the performance limits of the National 
Institute of Health (“Istituto Superiore Di Sanità. Prot. 16/01/2014-0001584,” n.d.). Municipalities 
exceeding at least one of the following limits were included in the contaminated area: PFOS: ≤ 0.03 
µg/L; PFOA: ≤ 0.5 µg/L; the sum of other PFAS: ≤ 0.5 µg/L. The sum of other PFAS included: 
perfluorobutyric acid (PFBA), perfluoropentanoic acid (PFPeA), perfluorohexanoic acid (PFHxA), 
perfluoroheptanoic acid (PFHpA), perfluorononanoic acid (PFNA), perfluorodecanoic acid (PFDeA), 
perfluorododecanoic acid (PFDoA), perfluoroundecanoic acid (PFUnA), perfluorohexane sulfonate 
(PFHxS), perfluorobutane sulfonate (PFBS). 
The choice of using the residence as a proxy of PFAS exposure is motivated by the fact that living 
nearby a chemical plant is the strongest predictor of blood levels of PFAS and that the consumption 
of contaminated tap water correlates with PFAS concentration in blood (Ingelido et al. 2018).   
A control area was chosen for comparison (Figure 1). The area includes 48 contiguous municipalities, 
far away from the contaminated area, and not exposed to PFAS contamination according to the 
performance limits of the National Institute of Health.  
2.2 Study population 
Pregnant women living in the contaminated and control area (between 2009 and 2015) were identified 
from the Veneto Region Birth Registry. A record linkage procedure was performed between the 
Veneto Region Birth Registry and the Veneto Region hospital discharge records to identify all women 
with a hospital admission for preeclampsia or GDM in the nine months before the delivery or at time 
of delivery.  
The hospital discharge record represents a compulsory data collection system of all hospital 
admissions in Italian hospitals facilities. Each hospital discharge record reports data about the subject 
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hospitalized (e.g., age, gender, residence), the hospitalization characteristics (e.g., type, duration, 
outcome), the reason of the hospitalization (diagnosis), and the type of interventions done during the 
hospitalizations. The diagnoses and the interventions are coded using the International Classification 
of Diseases – 9th revision – Clinical Modification (ICD-9-CM). Hospitalizations for preeclampsia 
and GDM have been identified using the ICD-9-CM diagnosis’ codes 642 and 648.8 (including all 
fourth e fifth digits specifications), respectively. The codes of interest can be reported both in the 
main and secondary diagnosis field.  
2.3 Statistical analysis 
Descriptive statistics was computed as percentage (absolute numbers) for categorical variables and 
Pearson chi-squared was performed. An alpha of 0.05 was used as the cut-off for significance. 
Analyses were performed using SAS software (version 9.4). 
3. Results 
During the study period, 45,853 pregnant women have been identified from the Veneto Region Birth 
Registry in the contaminated and control area (7,999 in the contaminated ones). Maternal 
characteristics are reported in Table 1.  Pregnant women in the contaminated area have been found to 
be more likely to be younger (p-value <0.001) and to come from a foreign country (especially North 
Africa, p-value <0.001) compared to those living in the control area. For what concern the obstetrical 
history, women in the control area were more likely to be first-time mothers compared to those in the 
contaminated area (p-value <0.001) and they were found to be slightly more likely to have twins (p-
value 0.011). 
The frequency of both preeclampsia and GDM derived from hospital discharge records has been 
found to be slightly higher in pregnant women living in the contaminated area compared to those 
living in the control ones (4.58% vs. 3.25% and 5.5% vs. 3.13%, for preeclampsia and GDM, 
respectively) (Table 2).  
4. Discussion 
This study is based on preliminary data and requires more work. For this reason, present results must 
be taken with caution since a medical chart review is ongoing to validate the cases of preeclampsia 
and GDM identified from the hospital discharge records. On the other side, it is worth pointing out 
that hospital discharge records are generally considered a reliable source for the identification of the 
most severe forms of preeclampsia (Roberts et al. 2008) and GDM (Devlin, Desai, and Walaszek 
2009). 
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Literature on the relationship between PFAS exposure and preeclampsia does not provide consistent 
results, as shown in the first chapter of the present work. Savitz et al. and Stein et al. have found out 
evidence of a weak association of PFOA with self-reported preeclampsia (Savitz, Stein, Bartell, et al. 
2012; Stein, Savitz, and Dougan 2009). Conversely, Starling et al. did not find any significant 
association between PFAS exposure and preeclampsia in Norwegian women (Starling et al. 2014). 
Other studies focused on pregnancy-induced hypertension instead of preeclampsia, showing a 
significant positive association with PFOA (Savitz, Stein, Elston, et al. 2012) and also PFOS (Darrow, 
Stein, and Steenland 2013). The fact that no consistent and strong associations were found between 
preeclampsia and PFAS exposure could be related to the heterogeneous approaches that were used to 
define the preeclampsia cases. Some studies have evaluated only pregnancy-induced hypertension 
(Savitz, Stein, Elston, et al. 2012; Darrow, Stein, and Steenland 2013), while the other studies have 
focused specifically on preeclampsia (Savitz, Stein, Bartell, et al. 2012; Stein, Savitz, and Dougan 
2009; Starling et al. 2014), which represents the most severe form of pregnancy-induced hypertension 
by involving the impairment of kidney function. Furthermore, Savitz et al. and Stein et al. (Savitz, 
Stein, Bartell, et al. 2012; Stein, Savitz, and Dougan 2009) considered self-reported preeclampsia 
(which is known to have a low positive predictive value (Stuart et al. 2013)) and only Starling et al. 
employed a validated definition of preeclampsia (Starling et al. 2014).  
As for preeclampsia, evidence about the relationship between PFAS exposure and GDM is still 
inconsistent. Two studies have found out a positive association between PFAS exposure and GDM 
(Zhang et al. 2015; Matilla-Santander et al. 2017). Conversely, two other recent studies on Chinese 
and Canadian pregnant women did not find a significant association between PFAS exposure and 
GDM (Wang et al. 2018; Shapiro et al. 2016). Again, different definitions of GDM cases were 
employed. Zhang et al. based their study on GDM self-reported by the women themselves (Zhang et 
al. 2015), while the other studies derived GDM cases from medical records (Matilla-Santander et al. 
2017; Wang et al. 2018; Shapiro et al. 2016).  
It is noteworthy that no previous studies have analysed the association between PFAS exposure and 
these outcomes in such a large sample of pregnant women. On the other hand, the definition used to 
identify PFAS exposure represents a study limitation since an indirect measure of exposure has been 
employed (woman residence), potentially leading to some misclassification. However, it has been 
demonstrated that living in a geographical area served by contaminated water supply is the strongest 
predictor of PFAS blood concentration (Steenland et al. 2009), so that maternal residence could be 
considered a good proxy of PFAS exposure.   
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5. Conclusions  
We will be waiting for further results from the validation process of GDM and preeclampsia cases 
through the review of the medical records (which is ongoing) in order to confirm or disconfirm the 
ones presented in this work.  
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Table 1. Maternal characteristics stratified according to maternal residence in the contaminated and 
control area. Data are percentages (absolute numbers) 
  
Contaminated area 
(n=7,999) 
Control area 
(n=37,854) P-value 
Maternal age    
   <24 11.83 (946)  8.78 (3,325) <0.001 
   25-34 58.17 (4653) 55.89 (21,157)  
   >35 30 (2,400) 35.33 (13,372)  
Nationality    
   Italian 67.22 (5,377) 70.92 (26,845) <0.001 
   European 0.6 (48) 1.23 (465)  
   Eastern European 10.23 (818) 13.46 (5,097)  
   North African 12.24 (979) 4.47 (1,693)  
   African 2.74 (219) 3.23 (1,221)  
   Middle Eastern 0.05 (4) 0.12 (46)  
   Chinese 0.8 (64) 2.28 (863)  
   South-East Asia 0.08 (6) 0.26 (98)  
   Other Asian 5.04 (403) 1.72 (652)  
   American 1.01 (81) 2.22 (839)  
   Oceanian 0 (0) 0.09 (35)  
Pregnancy 
   
   Singleton 98.67 (7,893) 98.28 (37,203) 0.011 
   Twin 1.33 (106) 1.72 (651)  
Parity 
   
   Primipara 46.27 (3,701) 49.48 (18,732) <0.001 
   Multipara 53.73 (4,298) 50.52 (19,122)   
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Table 2. Frequency of preeclampsia and gestational diabetes mellitus in the contaminated and in the 
control area. Data are percentages (absolute numbers). 
  Contaminated area (n=7,999) Control area (n=37,854) 
Preeclampsia   
   Yes 4.58 (366) 3.25 (1,232) 
   No 95.42 (7,633) 96.75 (36,622) 
Gestational Diabetes Mellitus   
   Yes 5.5 (440) 3.13 (1,183) 
   No 94.5 (7,559) 96.87 (36,671) 
 
 
 
  
67 
 
Figure 1. Contaminated area (red) and control area (green). Red: Albaredo D'Adige, Alonte, Arcole, 
Asigliano Veneto, Bevilacqua, Bonavigo, Boschi Sant'Anna, Brendola, Cologna Veneta, Legnago, Lonigo, Minerbe, 
Montagnana, Noventa Vicentina, Poiana Maggiore, Pressana, Roveredo di Gua', Sarego, Terrazzo, Veronella, Zimella. 
Green: Arcade,  Breda  di  Piave,  Carbonera,  Casale  sul  Sile,  Casier,  Castelfranco  Veneto,  Chiarano,  
Cimadolmo, Fontanelle,  Giavera  del  Montello,  Gorgo  al  Monticano,  Istrana,  Mansue',  Mareno  di  Piave,  
Maserada  sul Piave,  Mogliano  Veneto,  Monastier  di  Treviso,  Montebelluna,  Morgano,  Nervesa  della  Battaglia,  
Oderzo, Ormelle, Paese, Ponte di Piave, Ponzano Veneto, Povegliano, Preganziol, Quinto di Treviso, Resana, 
Roncade, Salgareda,  San  Biagio  di  Callalta,  San  Polo  di  Piave,  Santa  Lucia  di  Piave,  Silea,  Spresiano,  
Susegana, Trevignano,  Treviso,  Vazzola,  Vedelago,  Villorba,  Volpago  del  Montello,  Zenson  di  Piave,  Zero  
Branco, Fossalta di Piave, Marcon, Meolo, Noventa di Piave, Quarto D'altino 
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Birth outcomes in newborns of mothers living in an area contaminated by PFAS in Veneto 
Region 
1. Introduction 
Perfluoroalkylated substances (PFAS) are persistent organic pollutants that accumulate in the human 
body. PFAS enter the human body through ingestion (via contaminated drinking water and food, 
which are the main routes of exposure for the general population) and inhalation (which is the main 
route of exposure for workers). Such chemicals are distributed to the organs by binding serum 
albumin and accumulate mainly in the liver, the lungs, and the kidneys (Lau et al. 2007). In pregnant 
women, PFAS cross the placenta and accumulate in the fetus (F. Chen et al. 2017). PFAS also transfer 
from maternal blood to breast milk in lactating women, thus affecting breastfed infants (Cariou et al. 
2015). The transplacental and lactational route are the main sources of exposures to PFAS of the fetus 
and the breastfed child (Cariou et al. 2015). 
The evidence of transplacental and lactational transfer of PFAS arouses concern about the potential 
developmental effects of PFAS exposure. Several studies on both animals and humans have been 
published about the relationship between in-utero exposure to PFAS (especially to Perfluorooctanoic 
acid (PFOA) and perfluorooctane sulfonate (PFOS) - the PFAS most widely produced and studied) 
and adverse birth outcomes, focusing mainly on fetal growth. In laboratory animals, it has been shown 
that exposure to PFAS, and especially to PFOA, is associated with lower fetal and pups’ weight 
(Koustas et al. 2014). However, animals are exposed to higher doses of PFAS compared to humans. 
In a systematic review of the human evidence, Johnson and colleagues have concluded that there is 
sufficient evidence to support the existence of an association between PFOA exposure and the 
reduction of fetal growth (Johnson et al. 2014). Subsequently, a review by Bach et al. considered the 
relationship between PFOA/PFOS exposure and fetal growth, concluding that the evidence suggests 
the existence of the relationship but that the findings are still inconsistent (Bach et al. 2015). Several 
studies on human fetal growth have been published after the publication of these reviews. Most of 
them confirm the hypothesis that PFAS exposure is significantly (inversely) associated to fetal growth 
(Bach et al. 2016; Cao et al. 2018; M.-H. Chen et al. 2017; Li et al. 2017; Minatoya et al. 2017; Rokoff 
et al. 2018; Starling et al. 2017; Wang et al. 2016), although a few studies report no association (de 
Cock et al. 2016; Govarts et al. 2016; Gyllenhammar et al. 2018; Manzano-Salgado et al. 2017). 
Almost all these studies used birth weight (or other continuous endpoints such as birth length or head 
circumference) as the main index of fetal growth, even if its interpretation is not straightforward. 
Conversely, the small for gestational age (SGA), a measure based on birth weight and gestational age 
at birth, has been used only in a small number of studies (Lauritzen et al. 2017; Wang et al. 2016; 
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Govarts et al. 2018; M.-H. Chen et al. 2012; Manzano-Salgado et al. 2017; Whitworth et al. 2012; 
Hamm et al. 2010). However, SGA is a well-known proxy of intrauterine growth restrictions and a 
strong predictor of both short- and long-term morbidity (e.g., neurodevelopmental sequelae, high risk 
of suffering from metabolic and cardiovascular diseases in adulthood (Varvarigou 2010)) and 
mortality (Wennerström, Simonsen, and Melbye 2015).  
The present retrospective study aimed at assessing the relationship between PFAS exposure and the 
risk of SGA among newborns of mothers living in an area contaminated by PFAS in Veneto Region 
(Italy).  
2. Materials and Methods 
The study was conducted in an area within the Veneto Region, northeast Italy, where PFAS 
contamination of groundwater, surface water, and drinking water was detected in 2013. The area, of 
about 200 km2, crosses the province of Vicenza and, to a lesser extent, those of Verona and Padova. 
The source of the pollution was identified in a chemical plant located in the contaminated area. The 
main contaminant pathways were found to be the wastewater of the chemical plant and the water of 
the wastewater treatment (WHO 2017). At the time of the discovery of the contamination, 
concentrations of PFOA and PFOS in drinking water were found to be very high (1,475 ng/L and 117 
ng/L, respectively) (WHO 2017). 
The detection of the water pollution was quickly followed by remedial interventions aimed at 
containing drinking water contamination, using carbon filters (installed in the summer of 2013) 
(WHO 2017). This resulted in a marked drop of PFOA and PFOS concentrations in drinking water, 
observed within three months from the application of carbon filters (WHO 2017). However, it was 
established that the PFAS contamination had begun back in the 1960s (Dell’Acqua and Mazzola 
2017), which implies a long-term exposure to PFAS of the population living in the contaminated area.  
2.1 Exposure 
Maternal residence in the contaminated area reported in the birth certificate was used as a proxy of 
exposure to PFAS, since it has been demonstrated that living in a contaminated area and drinking tap 
water are strictly associated with serum PFAS (Ingelido et al. 2018). The contaminated area was 
defined as specified in a Veneto Region official resolution (Deliberazione della Giunta Regionale n. 
2133 del 23 dicembre 2016, n.d.) and included 21 municipalities, located in the South-West of Veneto 
Region, with higher concentrations of PFAS in the drinking water than the performance limits 
established by the Italian National Institute of Health (“Istituto Superiore Di Sanità. Prot. 16/01/2014-
0001584,” n.d.). Municipalities exceeding at least one of the following values were included in the 
contaminated area, PFOS: 0.03 µg/L; PFOA: 0.5 µg/L; sum of other PFAS: 0.5 µg/L 
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(perfluorobutyric acid (PFBA), perfluoropentanoic acid (PFPeA), perfluorohexanoic acid (PFHxA), 
perfluoroheptanoic acid (PFHpA), perfluorononanoic acid (PFNA), perfluorodecanoic acid (PFDeA), 
perfluorododecanoic acid (PFDoA), perfluoroundecanoic acid (PFUnA), perfluorohexane sulfonate 
(PFHxS), perfluorobutane sulfonate (PFBS)). A control area was chosen for comparison. The area 
includes 48 contiguous municipalities, far away from the contaminated area, and not exposed to PFAS 
contamination according to the performance limits of the National Institute of Health.   
2.2 Study population  
The study included all singletons live births reported in the Veneto Region Birth Registry between 
the 1st of January 2003 and the 31st of December 2017 from mothers living in the contaminated and 
the control area (according to maternal municipality of residence reported in the birth certificate). The 
Veneto Region Birth Registry represents a mandatory electronic data collection system of all births 
(included stillbirths) occurring in the Region. Information about each birth is recorded by the 
attending midwife and by the pediatrician in charge of the care of the newborn. Such information 
includes parental, pregnancy, delivery, and newborn (or stillbirth) characteristics. For the study, the 
information considered were: maternal socio-demographic characteristics (age, nationality, marital 
status, educational level, and working status), smoking habit, and obstetric history (parity, 
preeclampsia, adverse outcomes in previous pregnancies -stillbirth and abortion-).    
2.3 Outcome 
SGA was defined as birth weight <3rd percentile for the gestational age according to sex-specific 
Italian growth charts (Bertino et al. 2010). Data about gestational age, newborn gender, and birth 
weight for each singleton live birth were derived from the Veneto Region Birth Registry.  
2.4 Statistical analysis 
Descriptive statistic was reported as percentage (absolute number), and the Pearson chi square test 
was performed.  
Odds Ratio (OR) and 95% Confidence Intervals (C.I.) of the occurrence of SGA births in the 
contaminated and control area were calculated in a univariate analysis first and through stepwise 
logistic regression, including all the aforementioned maternal characteristics. Analyses were also 
conducted breaking down data into two periods, before and after the filters were applied, i.e., 2003-
2014 and 2015-2017. The 2014 was included in the period before filters’ installation because filters 
were installed in the summer of 2013 and the drop of PFAS in the drinking water took about 3 months. 
This means that pregnant women who gave birth in the first half of 2014 were exposed to PFAS 
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though the consumption of contaminated drinking water during at least the first trimester of the 
pregnancy. 
An alpha of 0.05 was used as the cut-off for significance. Analyses were performed using SAS 
software (version 9.4). 
3. Results 
There were 99,247 singletons live births in the contaminated and control area during the study period 
(17,021 in the contaminated area). Maternal and newborn characteristics stratified according to the 
area in which the mother lived are reported in Table 2. Mothers in the contaminated area were more 
likely to be younger (p-value <0.001), to come from a foreign country (especially from north Africa) 
(p-value <0.001), and to be married (p-value <0.001). They were also of lower socio-economic level 
(mothers in the control area were significantly more likely to have a high educational level and to 
have a job compared to mothers in the contaminated area). Regarding obstetric history, women in the 
contaminated area were less likely to be primiparies and, in case they had previous conceptions, they 
were less likely to have suffered from adverse outcomes (stillbirths and abortions).  
The prevalence of SGA was 3.41% (95% C.I. 3.15-3.70) in the contaminated area and 2.65% (95% 
C.I. 2.54-2.76) in the control ones. Table 3 shows the crude and adjusted association of residential 
exposure to PFAS (living in the contaminated area vs. control area) with SGA. Crude OR for SGA 
was 1.33 (95% C.I. 1.26-1.40) before the application of filters. The association remained significant 
even if lower in magnitude after the application of filters (1.15 95% C.I. 1.02-1.29). The multivariate 
analysis confirmed that living in the contaminated area significantly increased the odds of SGA (OR 
1.26 (95% C.I. 1.14-1.38)), also when the other explanatory variables preserved by stepwise 
regression were taken into account. The analyses stratified according to the period before and after 
filters showed that living in the contaminated area was significantly associated with SGA before 
filters’ application (OR 1.28 95% C.I. 1.15-1.42, 2003-2014), but the association was no more 
significant after that (1.14 95% C.I. 0.91-1.45, 2015-2017).  
4. Discussion 
These findings show that newborns of mothers living in the contaminated area are significantly more 
likely to be SGA compared to those of mothers living in the control area, with or without 
consideration of available covariates associated to the outcome. The odds of being SGA in the 
contaminated area decrease after deployment of filters reducing exposure. Such finding supports the 
hypothesis of a causal relationship between PFAS exposure and intrauterine growth restrictions, 
although the pathophysiological mechanism underlying a causal association between PFAS exposure 
and intrauterine growth restriction is not yet fully clear. PFAS seem to act as endocrine disruptors 
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leading to an impairment of thyroid hormones homeostasis (Ballesteros et al. 2017), which play a key 
role in fetal development. However, even if the studies on the effects of PFAS exposure on thyroid 
hormones have been carried out in both animal and humans, the evidence is still inconclusive. It has 
been suggested that intrauterine growth restrictions could depend on histopathological alterations of 
the placenta leading to lower placental transfer efficiency (Lee et al. 2015), but evidence in the field 
is available only for animals. Not least, it has been hypothesized that developmental toxicity depends 
on PFAS disturbance of the Peroxisome proliferator-activated receptors (PPARs) (Abbott 2009), 
which are nuclear receptors involved in the regulation of complex mechanisms related to development 
and metabolism. Also in that case, no definitive evidence is available. Clearly, that of the mechanism 
by which PFAS disrupt fetal growth is a research area that deserves further attention. 
Looking at the epidemiological evidence in the field, some other studies that investigated the 
relationship between PFAS exposure and the risk of SGA produced positive results, although not 
fully univocally. A significantly elevated OR for SGA in newborns of tobacco smoking mothers 
exposed to PFOA and PFOS in a pooled analysis of eight birth cohorts was previously documented 
(Govarts et al. 2018). Significantly higher odds for SGA in exposed to PFOS were also found in the 
Taiwan Birth Panel Study (TBPS) (M.-H. Chen et al. 2012). Another study conducted in Taiwan 
(Wang et al. 2016) found out a significant positive association with some long-chain PFAS (PFDeA 
and PFUnDA), but only in female newborns. Not least, the analysis of the association between SGA 
and PFAS in a prospective multicentre study conducted in Norway and Sweden showed a  statistically 
significant  OR of 5.25 (95% C.I. 1.68–16.4) for SGA in newborns exposed to PFOA in the Swedish 
cohort (Lauritzen et al. 2017). Conversely, some studies found no associations between PFAS 
exposure and SGA (Manzano-Salgado et al. 2017; Whitworth et al. 2012), and in one study PFOS 
was found to be protective for the risk of SGA (Hamm et al. 2010).  
A strength of the present study is its large number of observations (99,247 singleton live births), 
compared with all other studies published so far, presenting data on much smaller samples (no more 
than 5,500 mother-child pairs). This is remarkable since only a small portion of the newborn 
population is affected by SGA (by definition, less than 10%) and this might affect the accuracy in 
estimating the association between PFAS and this growth endpoint, especially if the study sample is 
small. Also, it is worth pointing out that this research work uses a more restrictive definition of SGA 
than in previous studies (weight <3rd percentile for gestational age instead of <10th percentile for 
gestational age), which should favour specificity over sensitivity, thereby diminishing the chances 
that our findings are false positives. On the other hand, an indirect measure of PFAS exposure was 
used (relying on the assumption that mothers living in the contaminated area were exposed to PFAS 
through contaminated drinking water consumption). This approximation is bound to produce some 
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misclassification, non-differtial in nature, in estimating the expsoure to PFAS (i.e., if a 
misclassification in PFAS expsoure occurs, it has been resulted in an underestimation of the 
magnitude of the association between PFAS expsoure and the outcome of interest). In addition to 
that, it has been shown that tap water consumption is correlated with serum levels of PFAS (Ingelido 
et al. 2018). Considering such a framework, the use of maternal residence in a geographical area 
served by a contaminated water supply could be considered a good proxy of PFAS exposure. 
 
5. Conclusions  
The findings of this study, the largest of its kind to date, suggest that PFAS plays a role in affecting 
fetal growth and they support the hypothesis of a causal association between PFAS exposure and 
SGA. However, the present topic deserves further research for what concerns the pathophysiological 
mechanisms potentially involved in the association between PFAS exposure and intrauterine growth.  
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Table 1. List of municipalities included in the contaminated and in the control area 
Area Municipalities 
Contaminated area Albaredo D'Adige, Alonte, Arcole, Asigliano Veneto, 
Bevilacqua, Bonavigo, Boschi Sant'Anna, Brendola, 
Cologna Veneta, Legnago, Lonigo, Minerbe, 
Montagnana, Noventa Vicentina, Poiana Maggiore, 
Pressana, Roveredo di Gua', Sarego, Terrazzo, Veronella, 
Zimella 
Control area Arcade,  Breda  di  Piave,  Carbonera,  Casale  sul  Sile,  
Casier,  Castelfranco  Veneto,  Chiarano,  Cimadolmo, 
Fontanelle,  Giavera  del  Montello,  Gorgo  al  
Monticano,  Istrana,  Mansue',  Mareno  di  Piave,  
Maserada  sul Piave,  Mogliano  Veneto,  Monastier  di  
Treviso,  Montebelluna,  Morgano,  Nervesa  della  
Battaglia,  Oderzo, Ormelle, Paese, Ponte di Piave, 
Ponzano Veneto, Povegliano, Preganziol, Quinto di 
Treviso, Resana, Roncade, Salgareda,  San  Biagio  di  
Callalta,  San  Polo  di  Piave,  Santa  Lucia  di  Piave,  
Silea,  Spresiano,  Susegana, Trevignano,  Treviso,  
Vazzola,  Vedelago,  Villorba,  Volpago  del  Montello,  
Zenson  di  Piave,  Zero  Branco, Fossalta di Piave, 
Marcon, Meolo, Noventa di Piave, Quarto D'altino  
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Table 2. Maternal and newborn characteristics stratified according to maternal residence in the 
contaminated and control area. Data are percentages (absolute numbers) 
  
Contaminated area  
(n= 17,021) 
Control area 
(n=82,226) 
P-value 
SGA   
 
   Yes 3.41 (578) 2.65 (2,168) <0.001 
   No 99.48 (16,359) 99.44 (79,616) 
 
Maternal age    
   <17 0.24 (41) 0.19 (157) <0.001 
   18-24 12.28 (2,091) 8.95 (7,360)   
   25-29 24.89 (4,238) 22.07 (18,148)   
   30-34 34.81 (5,926) 36.20 (29,767)   
   35-39 22.33 (3,802) 26.08 (21,448)   
   >40 5.42 (923) 6.49 (5,343)   
Nationality    
   Italian 69.79 (11,879) 72.73 (59,724) <0.001 
   European 0.63 (108) 1.24 (1,019)   
   Eastern European 9.80 (1,669) 12.50 (10,271)   
   North African 10.84 (1,845) 4.23 (3,474)   
   African 2.50 (427) 3.07 (2,527)   
   Middle Eastern 0.05 (9) 0.10 (87)   
   Chinese 0.72 (123) 2.27 (1,868)   
   South-East Asia 0.07 (13) 0.23 (192)   
   Other Asian 4.62 (788) 1.47 (1,213)   
   American 0.93 (159) 2.02 (1,659)   
   Oceanian 0 0.09 (78)   
Educational level    
   High 18.52 (3,145) 22.83 (18,501) <0.001 
   Medium 45.95 (7,801) 48.83 (39,577)   
   Low 35.51 (6,029) 28.33 (22,959)   
Working status    
   Housewife 29.67 (5,041) 23.28 (19,118) <0.001 
   Unemployed 9.70 (1,648) 7.26 (5,963)   
   Employed 60.62 (10,297) 69.45 (57,038)   
Marital status    
   Other 2.61 (444) 2.70 (2,213) <0.001 
   Married 79.74 (13,544) 76.15 (62,418)   
   Unmarried 17.64 (2,997) 21.14 (17,328)   
Parity 
   
   Primipara 47.32 (7,986) 49.01 (39,312) <0.001 
   Multipara 52.67 (8,890) 50.98 (40,894)   
Smoking habit 
   
   Yes 5.70 (958) 4.72 (3,753) <0.001 
   No 94.29 (15,833) 95.27 (75,742)   
Adverse outcomes in previous pregnancies    
   Yes 23.51 (3,745) 25.95 (19,401) <0.001 
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   No 76.48 (12,179) 74.04 (55,359)   
Preeclampsia    
   Yes 2.58 (422) 2.23 (1,755) 0.013 
   No 97.41 (15,894) 97.76 (76,923)   
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Table 3. Crude and adjusted OR (95% Confidence Intervals (C.I.)) for SGA (contaminated vs. 
control area) 
  Crude OR (95% C.I.) P-value Adjusted* OR (95% C.I.) P-value 
2003-2014 1.33 (1.26-1.40) <0.001 1.28 (1.15-1.42) <0.001 
2015-2017 1.15 (1.02-1.29) 0.013 1.14 (0.91-1.45) 0.24 
Overall 1.29 (1.24-1.36) <0.001 1.26 (1.14-1.38) <0.001 
*Maternal age, nationality, educational level, marital status, smoking habit, parity, preeclampsia, adverse outcomes in 
previous pregnancies -stillbirths and/or abortion-, newborn gender  
 
